The Pediatric Artificial Pancreas (PEDAP) trial: A [ADDRESS_1121350] University, [LOCATION_004]  16 
 17 
Coordinating Center  18 
Jaeb Center for Health Research  19 
 20 
 21 
 22 
  Version Number: v11 .0  / NCT# 04796779 23 
DECEMBER 3, 2021 24 
 
 PEDAP
 PROTOCOL V 11.0  CLEAN  PAGE 2 OF 84 
 KEY ROLES  25 
 
Sponsor  Chair / IDE Chair   
Name, degree Marc D. Breton , Ph.D. 
Institution Name  [CONTACT_199562], Center for Diabetes Technology  
  
Protocol Chair/Director   
Name, degree R. Paul Wadwa, MD  
Institution Name  [CONTACT_418106], University of Colorado  
 
JCHR Coordinating Center Director  
Name, degree John Lum, MS  
Institution Name  [CONTACT_418107], degree Roy Beck, M.D., Ph.D.  
Institution Name  [CONTACT_352741]  
 26 
  27 
 
 PEDAP
 PROTOCOL V 11.0  CLEAN  PAGE 3 OF 84 
 PROTOCOL VERSION HISTORY  28 
Version 
Number  Author(s)  Approver  Effective 
Date  Revision Description  
1.[ADDRESS_1121351] and 
Extension period and that associated body text agrees with visit window table text.  Initial 
version used for study.  
5.0 Shannon Hiser, John 
Lum  R. Paul Wadwa  7 May 2021  Addition of inclusion criterion requiring U.S. 
residency; typo correction in 9.2.[ADDRESS_1121352], inclusion of all study 
participants in the 13 week + 3 day call, 14- week 
call, and 15 -week visit  
8.0 John Lum  R. Paul Wadwa  10 Sep 2021  Addition of ancillary study during Extension 
Phase to obtain system performance data during meal/exercise challenges ; associated  revisions to 
Stats chapter , plus minor unrelated Stats edits.  
9.[ADDRESS_1121353] 2021  Revisions to exercise and meal bolus challenges 
to address IRB requests during IRB review  
11.0 John Lum  R. Paul Wadwa  03 Dec 2021  Introduction  of Extended Use period  
 29 
 
 PEDAP
 PROTOCOL V 11.0  CLEAN  PAGE 4 OF 84 
 TABLE OF CONTENTS  30 
CHAPTER 1: BACKGROUND INFORMATION  ............................................................................................. 22 31 
 Introduction .......................................................................................................................... 22  32 
 Rationale  .............................................................................................................................. 22  33 
 Potential Risks and Benefits of the Investigational Device ................................................. 23  34 
1.3.1 K
nown Potential Risks ................................................................................................... 23  35 
[IP_ADDRESS] Potential Risks and Benefits of the CLC System .................................................. 23  36 
[IP_ADDRESS] Risk of Hypoglycemia ........................................................................................... 23  37 
[IP_ADDRESS] Risk of Hyperglycemia .......................................................................................... 23  38 
[IP_ADDRESS] Fingerstick Risks .................................................................................................... 23  39 
[IP_ADDRESS] Subcutaneous Catheter Risks (CGM) .................................................................... 23  40 
[IP_ADDRESS] Risk of Device Reuse ............................................................................................. 24  41 
[IP_ADDRESS] Questionnaires and Focus Groups ......................................................................... 24  42 
[IP_ADDRESS] Other Risks ............................................................................................................ 24  43 
1.3.2 Known Potential Benefits .............................................................................................. 25  44 
1.3.3 Risk Assessment ............................................................................................................ 25  45 
 General Considerations  ........................................................................................................ 25  46 
CHAPTE R 2: STUDY ENROLLMENT AND SCREENING  .............................................................................. 27 47 
 Participant Recruitment and Enrollment .............................................................................. 27  48 
2.1.1 I
nformed Consent and Authorization Procedures .......................................................... 27  49 
 Participant Inclusion Criteria  ............................................................................................... 27  50 
 Participant Exclusion Criteria  .............................................................................................. 28  51 
 Eligibility Assessment and Baseline Data Collection .......................................................... 29  52 
 Historical Information .......................................................................................................... 29  53 
 Screening Testing and Procedures ....................................................................................... 29  54 
 Screen Failures  ..................................................................................................................... 30  55 
CHAPTER 3: CGM  RUN-IN PHASE ............................................................................................................ 31 56 
 CGM Run -in Phase Overview  ............................................................................................. 31  57 
 Initiation of CGM  ................................................................................................................ 31  58 
3.2.1 C
GM Training ................................................................................................................ 31  59 
 Blood Glucose and Ketone Testing ..................................................................................... 32  60 
 Assessment of Successful Completion of the Run-in Phase................................................ 32  61 
 
 PEDAP
 PROTOCOL V 11.0  CLEAN  PAGE 5 OF 84 
 
 Optimization of Insulin Therapy.......................................................................................... 33  62 
CHAPTER 4: RANDOMIZATION VISIT ....................................................................................................... 34 63 
 Visit Timing  ......................................................................................................................... 34  64 
4.1.1 R
andomization ............................................................................................................... 34  65 
4.1.2 Baseline HbA1c Determination ..................................................................................... 34  66 
CHAPTER 5: MAIN STUDY PROCEDURES  ................................................................................................. [ADDRESS_1121354]  .................................................................................................. 39  81 
5.4.3 2- Week Visit  .................................................................................................................. 39  82 
 Follow-up Visits and Phone Contacts for Both Groups ...................................................... 40  83 
5.5.1 V
isits .............................................................................................................................. 40  84 
5.5.2 Phone Contacts............................................................................................................... 40  85 
5.5.3 Optimization of Insulin Therapy .................................................................................... 40  86 
5.5.4 13- Week Visit  ................................................................................................................ 41  87 
 Early Termination Visit (If Applicable)  .............................................................................. 41  88 
 Unscheduled Visits .............................................................................................................. 41  89 
CHAPTER 6: EXTENSION PHASE PROCEDURES  ....................................................................................... [ADDRESS_1121355] Schedule .................................................................................................. 42  91 
 Study Pump Initiation  .......................................................................................................... 42  92 
 Visits, Videoconferences, and Phone Calls for All Participants.......................................... 43  93 
6.3.1 13
-Week + [ADDRESS_1121356] ................................................................................................ 43  95 
6.3.3 15- Week Visit  ................................................................................................................ 43  96 
6.3.4 19- Week Visit  ................................................................................................................ 43  97 
6.3.5 23- Week Phone Call ...................................................................................................... 43  98 
6.3.6 26- Week Visit  ................................................................................................................ 43  99 
6.3.7 Optimization of Insulin Therapy .................................................................................... 43  100 
 Unscheduled Visits .............................................................................................................. 43  101 
 Participant Access to Study Device at Study Closure ......................................................... 44  102 
CHAPTER 7: EXTENDED USE PERIOD PROCEDURES  ............................................................................... [ADDRESS_1121357]  .................................................................................................. 46  109 
 Visits, Videoconferences, and Phone Calls for All Participants.......................................... 46  110 
7.3.1 13
-Week Visit and Subsequent Visits Every 13 Weeks ................................................ 46  111 
7.3.2 Fi nal Visit....................................................................................................................... 46  112 
7.3.3 Optimization of Insulin Therapy .................................................................................... 46  113 
 Unscheduled Visits .............................................................................................................. 47  114 
 Partic ipant Access to Study Device at Study Closure ......................................................... 47  115 
CHAPTER 8: STUDY DEVICES  .................................................................................................................... 48 116 
 Description of the Investigational Device ........................................................................... 48  117 
8.1.1 I
nsulin Pump .................................................................................................................. 48  118 
8.1.2 Continuous Glucose Monitoring .................................................................................... 48  119 
8.1.3 Blood Glucose Meter and Strips .................................................................................... 48  120 
8.1.4 Ketone Meter and Strips ................................................................................................ 48  121 
8.1.5 Study Device Accountability Procedures ...................................................................... 48  122 
8.1.6 Blood Ketone Testing .................................................................................................... 48  123 
 Safety Measures  ................................................................................................................... 48  124 
8.2.1 C
GM Calibration ........................................................................................................... 48  125 
8.2.2 System Failure  ............................................................................................................... 49  126 
8.2.3 Hypoglycemia Threshold Alert and Safety Protocol ..................................................... 49  127 
 
 PEDAP
 PROTOCOL V 11.0  CLEAN  PAGE 7 OF 84 
 8.2.4 Hyperglycemia Threshold Alert and Safety Protocol .................................................... 49  128 
CHAPTER 9: TESTING PROCEDURES , QUESTIONNAIRES , AND FOCUS GROUPS  .................................... 51 129 
 Laboratory Testing ............................................................................................................... 51  130 
9.1.1 HbA1c: ........................................................................................................................... 51  131 
 Questionnaires ..................................................................................................................... 51  132 
9.2.1 P
edsQL Diabetes Module – Parent  ................................................................................ 51  133 
9.2.2 Pediatric Inventory for Parents ...................................................................................... 51  134 
9.2.3 INSPI[INVESTIGATOR_66681] – Parent  .............................................................................................. 51  135 
9.2.4 Pi[INVESTIGATOR_2272] (PSQI) – Parent ............................................................ 52  136 
9.2.5 Hypoglycemia Fear Survey- Parent (HFS -P) ................................................................. 52  137 
9.2.6 Hypoglycemia Confidence Scale ................................................................................... 52  138 
9.2.7 System Usability Scale (SUS) ....................................................................................... 52  139 
 Focus Groups ....................................................................................................................... 53  140 
CHAPTER 10: UNANTICIPATED PROBLEM , ADVERSE EVENT , AND DEVICE ISSUES REPORTING  ........ 54 141 
 Unanticipated Problems ..................................................................................................... 54  142 
 Adverse Events  .................................................................................................................. 54  143 
10.2.1 D
efinitions.................................................................................................................... 54  144 
10.2.2 Reportable Adverse Events .......................................................................................... 55  145 
10.2.3 Hypoglycemic Events .................................................................................................. 56  146 
10.2.4 Hyperglycemic/Ketotic Events .................................................................................... 56  147 
10.2.5 Relationship of Adverse Event to Study Device.......................................................... 57  148 
10.2.6 Severity (Intensity) of Adverse Events ........................................................................ 57  149 
10.2.7 Expectedness ................................................................................................................ 58  150 
10.2.8 Coding of Adverse Events ........................................................................................... 58  151 
10.2.9 Outcome of Adverse Events ........................................................................................ 58  152 
 Reportable Device Issues  ................................................................................................... 59  153 
 Timing of Event Reporting ................................................................................................ 59  154 
 Safety Oversight ................................................................................................................ 60  155 
 Stoppi[INVESTIGATOR_2121] ................................................................................................................ 60  156 
10.6.1 P
articipant Discontinuation of Study Device ............................................................... 60  157 
10.6.2 Criteria for Suspending or Stoppi[INVESTIGATOR_3396] ..................................................... 61  158 
CHAPTER 11: MISCELLANEOUS CONSIDERATIONS  ................................................................................. 62 159 
 Drugs Used as Part of the Protocol .................................................................................... 62  160 
 
 PEDAP
 PROTOCOL V 11.0  CLEAN  PAGE 8 OF 84 
 
 Collection of Medical Conditions and Medications .......................................................... 62  161 
 Prohibited Medications, Devices, Tr eatments, and Procedures ......................................... 62  162 
 Precautionary Medications, Treatments, and Procedures .................................................. 62  163 
 Prophylactic Medications, Treatments, and Procedures .................................................... 62  164 
 Rescue Medications, Treatments, and Procedures ............................................................. 63  165 
 Participant Compensation  .................................................................................................. 63  166 
 Participant Withdrawal ...................................................................................................... 63  167 
 Confidentiality  ................................................................................................................... 63  168 
CHAPTER 12: STATISTICAL CONSIDERATION  ......................................................................................... 64 169 
 Statistical and Analytical Plans .......................................................................................... 64  170 
 Statistical Hypotheses  ........................................................................................................ 64  171 
 Sample Size........................................................................................................................ 64  172 
 Efficacy Outcome Measures  .............................................................................................. 65  173 
12.4.1 P
rimary Efficacy Endpoint .......................................................................................... 65  174 
12.4.2 Secondary Efficacy Endpoints ..................................................................................... 65  175 
[IP_ADDRESS] Secondary Efficacy Endpoints Included in Hierarchical Analysis ...................... 65  176 
[IP_ADDRESS] Other Secondary Efficacy Endpoints ................................................................... 65  177 
12.4.3 CGM Metrics Calculations .......................................................................................... 66  178 
 Analysis Datasets and Sensitivity Analyses  ...................................................................... 67  179 
12.5.1 P
er Protocol Analyses .................................................................................................. 67  180 
12.5.2 Other Sensitivity Analyses ........................................................................................... 67  181 
 Analysis of the Primary Efficacy Endpoint ....................................................................... 68  182 
 Analysis of the Secondary Endpoints ................................................................................ 68  183 
12.7.1 H
ierarchical Analyses .................................................................................................. 68  184 
12.7.2 Other Endpoint Analyses ............................................................................................. 69  185 
 Safety Analyses .................................................................................................................. 70  186 
 Intervention Adherence...................................................................................................... 71  187 
 Protocol Adherence and Retention .................................................................................. 71  188 
 Baseline Descriptive Statistics  ......................................................................................... 71  189 
 Device Issues  ................................................................................................................... 72  190 
 Planned Interim Analyses  ................................................................................................ 72  191 
 Subgroup Analyses .......................................................................................................... 72  192 
 Multiple Comparison/Multiplicity  ................................................................................... 73  193 
 
 PEDAP
 PROTOCOL V 11.0  CLEAN  PAGE 9 OF 84 
 
 Exploratory Analyses ....................................................................................................... 73  194 
 Extension Phase ............................................................................................................... 74  195 
12.17.1 E
xclusion of Ancillary Study Data ............................................................................ 75  196 
 Extended Use Period ........................................................................................................ 75  197 
CHAPTER 13: DATA COLLECTION AND MONITORING  ............................................................................ 76 198 
 Case Report Forms and Device Data  ................................................................................. 76  199 
 Study Records Retention ................................................................................................... 76  200 
 Quality Assurance and Monitoring .................................................................................... 76  201 
 Protocol Deviations............................................................................................................ 77  202 
CHAPTER 14: ETHICS /PROTECTION OF HUMAN PARTICIPANTS  ............................................................ [ADDRESS_1121358]  ................................................................................................................. 78  204 
 Institutional Review Boards............................................................................................... 78  205 
 Informed Consent Process ................................................................................................. 78  206 
14.3.1 C
onsent Procedures and Documentation ..................................................................... 78  207 
14.3.2 Participant and Data Confidentiality ............................................................................ 78  208 
CHAPTER 15: ANCILLARY STUDY TO TEST CONTROL -IQ SYSTEM WITH MEAL BOLUS AND EXERCISE 209 
CHALLENGES  ............................................................................................................................................. 80 210 
 Objective  ............................................................................................................................ 80  211 
 Sample Size........................................................................................................................ 80  212 
 Eligibility  Criteria  .............................................................................................................. 80  213 
 Study Procedures ............................................................................................................... 80  214 
 Outcomes and Analysis Plan  ............................................................................................. 82  215 
Saf
ety Monitoring ...................................................................................................................... 83  216 
CHAPTER 16: REFERENCES  ....................................................................................................................... [ADDRESS_1121359] OF ABBREVIATIONS  219 
ABBREVIATION  DEFINITION  
AP Artificial Pancreas  
BG Blood Glucose  
BT/BTLE  Bluetooth, Bluetooth low energy  
CRF Case Report Form  
CGM Continuous Glucose Monitoring System  
CLC Closed -Loop Control  
CSII Continuous Subcutaneous Insulin Injection  
CTR Control -to-Range  
DiAs Diabetes Assistant  
DKA Diabetic Ketoacidosis  
EC European Commission  
FDA Food and Drug Administration  
GCP Good Clinical Practice  
HbA1c  Hemoglobin A1c  
ID Identification  
iDCL International Diabetes Closed Loop  
IDE Investigational Device Exemption  
IOB Insulin-on -Board  
IQR Interquartile Range  
JDRF Juvenile Diabetes Research Foundation  
LGS  Low Glucose Suspend  
PLGS  Predictive Low Glucose Suspend  
POC Point -of-Care 
QA Quality Assurance  
QC Quality Control  
RBM Risk-Based Monitoring  
RCT Randomized Control Trial  
SC Standard of Care group  
SD Standard Deviation  
TDD Total Daily Dose  
UI User Interface  
 220 
221 
 
 
 PEDAP
 PROTOCOL V 11.0  CLEAN  PAGE 11 OF 84 
 Signature [CONTACT_3490]  222 
Translation of the UV A Advanced Automated Insulin Delivery 223 
Systems to Clinical Care in Young Children: Glycemic Control, 224 
Regulatory Acceptance, and Optimization of Day to Day Use  225 
Protocol Identifying Number: PEDAP  226 
IND/IDE Sponsor: University of Virginia  227 
Version Number: 11 .0 228 
03 DEC  2021 229 
 
Protocol Chair   
Name, Institution  R. Paul Wadwa, M.D.  / University of Colorado – Barbara Davis Center  
Signature/Date   
 
Sponsor (IDE Holder)   
Name/Institution  Marc D. Breton , Ph.D. / University of Virginia  
Signature/Date   
 
Coordinating Center Director  
Name, Institution  John Lum, MS  / Jaeb Center for Health Research  
Signature/Date   
 
Medical Monitor   
Name, Institution  Roy Beck, MD, Ph.D . / Jaeb Center for Health Research  
Signature/Date   
 
 
 PEDAP
 PROTOCOL V 11.0  CLEAN  PAGE 12 OF 84 
 CLINICAL CENTER PRINCIPAL INVESTIGATOR [INVESTIGATOR_418069] 230 
COMPLIANCE  231 
Protocol Title:  The Pediatric Artificial Pancreas (PEDAP) trial: A Randomized Controlled [ADDRESS_1121360] of Care in Young Children in 233 
Type 1 Diabetes  234 
Protocol Version/Date: 11 .0 / [ADDRESS_1121361] read the protocol specified  above.  I n my formal capacity as a Clinical Center Principal 236 
Investigator, my duties include ensuring the safety of the study participants enrolled under my 237 
supervision and providing the Jaeb Center for Health Research , with complete and timely 238 
information, as outlined in the protocol.  It is understood that all information pertaining to the 239 
study will be held strictly confidential and that this confidentiality requirement applies to all 240 
study staff at this clinical center . 241 
This trial will be carried out in accordan ce with ICH E6 Good Clinical Practice (GCP) and as 242 
required by [CONTACT_716]: [LOCATION_002] (US) Code of Federal Regulations (CFR) applicable to 243 
clinical studies (45 CFR Part 46, 21 CFR Part 50, 21 CFR Part 56, 21 CFR Part 312, and/or 21 244 
CFR Part 812). [ADDRESS_1121362] (IRB), or other approved Ethics Committee, exc ept where necessary [ADDRESS_1121363](s) to the trial participants.  249 
All key personnel (all individuals responsible for the design and conduct of this trial) have [ADDRESS_1121364] of this study are 252 
informed about their obligations in meeting the above commitments. 253 
Investigator’s Signature __________________________________ Date: _____ / _____ / _____ 254 
 dd mmm  yyyy  255 
Investigator’s Name: ____________________________________ 256 
Clinical Center Name/Number: _____________________________________ 257 
 
 
 PEDAP
 PROTOCOL V 11.0  CLEAN  PAGE 13 OF 84 
 PROTOCOL SUMMARY  258 
PARTICIPANT AREA  DESCRIPTION  
Title The Pediatric Artificial Pancreas (PEDAP) trial: A Randomized 
Controlled Comparison of the Control -IQ technology Versus Standard 
Care in Young Children in Type [ADDRESS_1121365] 
care (defined as either multiple daily injections of insulin [MDI ] or use of 
an insulin pump without hybrid closed-loop control capabilities [low -
glucose suspend or predictive low -glucose suspend functionality is 
permitted ]) in youth age 2 to <6 years  old. 
Investigational Device  t:slim X2 with Control-IQ and Dexcom G6 system  
Objectives  The objective of the study is to assess efficacy , quality of life,  and safety 
of a closed loop control  (CLC) system (t:slim X2 with Control-IQ 
Technology) in a randomized controlled trial  with partial crossover . 
Study Design  First phase: a 13 -week parallel group r andomized clinical trial with 2 :[ADDRESS_1121366] care (SC); Second Phase: foll owing the RCT, a 13-week period where the 
Standard Care (SC) group will transition to use CLC and the experimental arm will extend the use of CLC for the same period . After 26 weeks, 
participants may continue using CLC for an additional Extended Use 
period . A subset of participants will be invited to join an optional 
exercise/meal challenge ancillary study.  
Number of Clinical Centers  ~[ADDRESS_1121367]  is time in target range 70 -180 mg/dL  
(TIR) measured by [CONTACT_418087]. SC  group over [ADDRESS_1121368] 6 months  
2. Familiarity and use of a carbohydrate ratio for meal boluses.  
3. Age ≥2 and < 6 years old  
4. Living with one or more parent/legal guardian knowledgeable about 
emergency procedures for severe hypoglycemia and able to contact [CONTACT_810859].  
5. Investigator has confidence that the parent can successfully operate all study devices and is capable of adhering  to the protocol  
6. Willingness to switch to lispro (Humalog) or aspart (Novolog) if not using already, and to use no other insulin besides lispro (Humalog) 
or aspart (Novolog) during the study for participants using a study-
provided Tandem pump during the st udy. 
7. Total daily insulin dose (TDD) at least 5 U/day  
8. Body weight at least 20 lbs  
 
 
 PEDAP
 PROTOCOL V 11.0  CLEAN  PAGE 14 OF 84 
 PARTICIPANT AREA  DESCRIPTION  
9. Willingness not to start any new non -insulin glucose -lowering agent 
during the course of the trial  
10. Participant and parent(s)/guardian(s) willingness to participate in all 
training sessions as directed by [CONTACT_464].  
11. Parent/guardian proficient in reading and writing English  
12. Live in the [LOCATION_002], with no plans to move outside the United 
States during the study period  
 
Exclusion Criteria   
1. Concurrent use of any non-insulin g lucose -lowering agent (including 
GLP -1 agonists, Symlin, DPP -4 inhibitors, SGLT -2 inhibitors, 
sulfonylureas).  
2. Hemophilia or any other bleeding disorder  
3. History of >[ADDRESS_1121369] 3 months  
4. History of >[ADDRESS_1121370] of employment who is also directly involved in conducting the clinical trial (as a study investigator, coordinator, etc.); or having a first -
degree relative who is directly involved in conducting the clinical trial 
Sample Size  Up to 150 screened  participants with the goal of randomizing 10 2 
participants.  
Treatment Groups  • Intervention Group: t:slim X2 with Control -IQ Technology and 
Study CGM.  
• Control Group: Standard care ( SC) - defined as either multiple daily 
injections of insulin ( MDI ) or use of a n insulin pump without  hybrid 
closed -loop control capabilities (low -glucose suspend or predictive 
low-glucose  suspend  functionality is permitted)  in conjunction with 
study CGM  
All participants  will be offer ed to extend the study for a n additional 13 
weeks , with the SC group switching to the t:slim X2 with Control-IQ  
System a fter the 13-week  RCT period . After 26 weeks, participants may 
continue using CLC for an additional Extended Use p eriod.   
Participant Duration  ~26-[ADDRESS_1121371] and Extension Phase , depending on duration of 
run-in phase; up to an additional ~7 months in Extended Use period  
Protocol Overview/Synopsis  After consent is signed, eligibility will be assessed.  Eligible participants not currently using an insulin pump and Dexcom G5 or Dexcom G6 CGM 
with minimum data requiremen ts will initiate a run -in phase of 2 to 6 
weeks that will be customized based on whether the participant is already 
 
 
 PEDAP
 PROTOCOL V 11.0  CLEAN  PAGE 15 OF 84 
 PARTICIPANT AREA  DESCRIPTION  
a CGM user.  Participants who skip or successfully complete the run -in 
will be randomly assigned 2 :1 to an intervention using  Tandem t:slim X2 
with Control-IQ Technology  or the standard care control group using 
existing insulin therapy in conjunction with study CGM . All participants 
will  continue their participat ion by [CONTACT_10540] t:slim X2 with Control-IQ 
system in an  Extension Phase. [ Figure 1] After 26 weeks, participants 
may continue using CLC for an additional Extended Use p eriod  through 
no later than July 31, 2022. A subset of participants will complete an 
optional exercise/meal challenge ancillary study.  
 259 
  260 
 
 
 PEDAP
 PROTOCOL V 11.0  CLEAN  PAGE 16 OF 84 
  261 
Figure 1: Study Design: Participants Randomized 2:1 Control- IQ Control (CLC) vs. [ADDRESS_1121372] Care (SC) Groups . Extension phase with partial crossover of SC G roup 263 
switching to use Control- IQ. Subsequent Extended Use period  through no later than July 264 
31, 2022. 265 

 
 
 PEDAP
 PROTOCOL V 11.0  CLEAN  PAGE 17 OF 84 
 SCHEMATIC OF STUDY DESIGN  266 
 267 
Figure 2: Overview of Study Design   268 
Screening/ Enrollment  
•Eligibility assessment and informed consent  
•Device download and adherence assessment for current CGM user  
 
CGM Placement/Training  
2-6 Week Run-In with  home use of study CGM   
       
Run-in Review  
Reassess Eligibility  
 
Randomization  
 
Eligible  
To Skip 
Run-In*? 
No 
Yes 
*Current u se of  Dexcom G5  or G6 CGM wit h readings captured on at least  
[ADDRESS_1121373]; start of Extension Phase - 
all participants use Control -IQ 
[ADDRESS_1121374]  
       
13-Week Extension Phase  
       
End of Study  
Extended Use P eriod through July 31, 2022  
 
 
 PEDAP
 PROTOCOL V 11.0  CLEAN  PAGE 18 OF 84 
  269 
Figure 3:  Schematic of Study Design (Post-Randomization through 26 Weeks ) [ADDRESS_1121375]:  Week 10  
Videoconference or Clinic Visit: Weeks 6, 13 
 
 
Study pump 
training and 
transition to  
study pump 
Primary Outcome  
 (13 weeks)  
CLC Group  
 SC Group  
Continued use of study 
closed -loop system  
 
Continued use of study 
CGM along with current 
insulin delivery (MDI or 
personal pump)  
Continued use of study CGM along with 
current insulin delivery  
Week [ADDRESS_1121376]  
System  data assessment  
Study pump training and transitions as shown 
above for CLC Group , then use of updated 
Control- IQ system for 13 weeks  
Videonconference/ Phone Contact: [CONTACT_2006] 3;  
Phone Contact: [CONTACT_41585] 14, 23;  
Videoconference  or Clinic Visit : Weeks 15, 19  
  
End of Extension Phase  (26 weeks)  
Transition to updated Control -IQ closed -
loop system for 13 additional weeks. 
Training will be provided on new features.  
Videonconference/ Phone Contact: [CONTACT_2006] 3;  
Phone Contact: [CONTACT_41585] 14, 23;  
Videoconference or Clinic Visit : Weeks 15, 19  
  
 
 MDI User?  
Study pump training and 
transition from MDI to pump 
Yes 
 No 
3-Day Videoconference or Call  
Pump settings adjustment  
Week [ADDRESS_1121377]  
CGM data assessment  
CLC Group  
 SC Group  
 
 
 PEDAP
 PROTOCOL V 11.0  CLEAN  PAGE 19 OF 84 
  271 
Figure 4:  Schematic of Study Design (Extended Use Period ) 272 
Study pump retraining visit and 
transition back to study pump 
 
No 
 Yes 
Gap between 26 -Week visit and 
start of Extended Use phase? 
Continued use of study 
closed -loop system  
Continued use of study 
closed -loop system  
Videoconference /Phone Contact  
[CONTACT_2006] 3; Week 1  
Every 13 Weeks  
Videoconference/Clinic Visit  
Final Visit; E nd of Study * 
* Final Visit to occur no later than July 31,  2022  
 
 
 PEDAP
 PROTOCOL V 11.0  CLEAN  PAGE 20 OF 84 
  273 
1 Only for participants on MDI at enrollment  assigned to the CLC group   274 
 275 
Table 1. Schedule of Study Visits and Procedures  (through 26- Week Visit)  276 
  277  Pre Pre 0 3d1 1w 2w 6w 10w 13w 13w + 
3d 14w 15w 19w 23w 26w 
Visit (V) , 
Videoconference (VC),  
or Phone (P)  VC/V VC/V VC/V VC/ 
P P VC/V  VC/
V P VC/
V VC/ 
P P VC/
V VC/
V P VC/
V 
Comment  Screen/
Enroll  Run- in Rand              
Eligibility Assessment  X X X             
HbA1c (Central lab)    X      X      X 
Device Data 
download (s) X X X X X X X X X X X X X X X 
Review diabetes 
management and AEs   X X X X X X X X X X X X X X 
Questionnaires as 
defined in section  9.2 X        X      X 
 
 
 PEDAP
 PROTOCOL V 11.0  CLEAN  PAGE 21 OF 84 
  278 
 279 
 280 
 281 
 282 
 283 
 284 
 285 
 286 
1 Participants are eligible to initiate Extended Use period if they completed the 26 -Week Visit within the prior 4 months  287 
2 Only for participants who had a gap between the 26 -Week Visit and the initiation of the Extended Use period during  288 
which they stopped use of the study pump and reverted to MDI or personal pump insulin therapy  289 
 290 
Table 2. Schedule of Study Visits and Procedures  (Extended Use Period ) 291 
 292 
 293 Days/Weeks after  
26-Week Visit =>  02 3d2 1w2 13w 26w, 39w, 
etc. Final 
Visit  
Visit (V) , 
Videoconference (VC),  
or Phone (P)  VC/V VC/ 
P VC/ 
P VC/V  VC/V  VC/V  
Eligibility Assessment1,2 X      
Study Pump Retraining2 X      
HbA1c (Central lab)     X X  
Device Data download (s)  X X X X X 
Review diabetes 
management and AEs   X X X X X 
 
 
 PEDAP
 PROTOCOL V 11.0  CLEAN  PAGE 22 OF 84 
 Chapter 1:  Background Information [ADDRESS_1121378]- generation closed -loop 296 
control (CLC) system retaining the same control algorithm that was initially tested by [CONTACT_137348]’s DiAs 297 
system and then implemented in the inControl system (TypeZero Technologies, Inc.). 298 
The system has received FDA approval for  use in individuals ≥ 6 years old following a pair of 299 
pi[INVESTIGATOR_810856]’s safety and efficacy, first in participants ≥1 4 years old 300 
(1) and then subsequently in participants ≥ 6 years old  (2).  301 
Closed -Loop Control System 302 
The Closed -Loop Control System contained in t -slim X2 with Control -IQ Technology is described  303 
in Master File MAF -2032/A008. Control -IQ Technology is derived from inControl previously 304 
described in IDE# G160097, G160181, G150240 and G140169/S010. The CLC is an “artificial 305 
pancreas” (AP) application that uses advanced closed loop control algorithms to automatically 306 
manage blood glucose levels for people with Type 1 Diabetes. The system modulates insulin to 307 
keep blood glucose in a targeted range. The system components include the  t:slim X2 with 308 
Control-IQ Technology and the Dexcom CGM G6. 309 
 310 
Figure 5. t:slim X2 with Control -IQ and Dexcom G6 system [ADDRESS_1121379] care. In addition, the data 314 
from this trial may be used for subsequent regulatory submiss ions for this system  in the age group 315 
studied. 316 
The extension phase will allow for additional exposure time to the Tandem t:slim X2 with Control- 317 
IQ Technology and evaluation of the SC arm after crossing over to use Control -IQ for a 13-week  318 
period.  319 

 
 
 PEDAP
 PROTOCOL V 11.0  CLEAN  PAGE 23 OF 84 
 
 Potentia l Risks and Benefits of the Investigational Device 320 
Risks and Benefits are detailed below. Loss of confidentiality is a potential risk; however, data are 321 
handled to minimize this risk.  Hypoglycemia, hyperglycemia and ketone formation are always a 322 
risk in participants with type 1 diabetes and participants will be monitored for these events . 323 
 
 324 
[IP_ADDRESS] Potential Risks and Benefits of the CLC System  325 
Even though the study system has been tested prior to this study, there is still a risk that parts of 326 
the system may not function properly. The following are possible reasons the system may deliver 327 
too much insulin or incorrectly stop insulin delivery: 328 
• CGM sensor reads higher or lower than the actual glucose level which increases risk for 329 
hypoglycemia and hyperglycemia with automated insulin delivery s ystem; 330 
• Device malfunctions that could produce a suspension of insulin delivery or over delivery 331 
of insulin. 332 
[IP_ADDRESS] Risk of Hypoglycemia 333 
As with any person having type 1 diabetes and using insulin, there is always a risk of having a low 334 
blood sugar (hypoglycemia).  The frequency of hypoglycemia should be no more and possibly less [ADDRESS_1121380] as at home, there is the possibility of fainting or seizu res 337 
(convulsions) and that for a few days the participant may not be as aware of symptoms of 338 
hypoglycemia.  A CGM functioning poorly and significantly over -reading glucose values could 339 
lead to inappropriate insulin delivery. 340 
[IP_ADDRESS] Risk of Hyperglycemia  341 
Hyperglyc emia and ketonemia could occur if insulin delivery is attenuated or suspended for an 342 
extended period or if the pump or infusion set is not working properly.  A CGM functioning poorly 343 
and significantly under -reading glucose values could lead to inappropriate suspension of insulin 344 
delivery. 345 
[IP_ADDRESS] Fingerstick Risks  [ADDRESS_1121381] for several weeks.  The risk of local infection is less than 1 in 1000.  This should 350 
not be a significant contributor to risks in this study as fi ngersticks are part of the usual care for 351 
people with diabetes. 352 
[IP_ADDRESS] Subcutaneous Catheter Risks (CGM)  353 
Participants using the CGM will be at low risk for developi[INVESTIGATOR_007] a local skin infection at the site of 354 
the sensor needle placement.  If a catheter is left under the skin for more than 24 hours , it is possible 355 
 
 
 PEDAP
 PROTOCOL V 11.0  CLEAN  PAGE 24 OF 84 
 to get an infection where it goes into the skin, with swelling, redness and pain.  There may be 356 
bleeding where the catheter is put in and bleeding under the skin causes a bruise (1 in 10 risk). [ADDRESS_1121382] a small portion of the sensor under the skin that may cause redness, swelling or pain at the 359 
insertion site.  The participant should be further instructed to notify the study coordinator 360 
immediately if this occurs.  361 
[IP_ADDRESS] Risk of Device Reuse  362 
The study CGM system is labeled for single use only. The sensor (the component of the system 363 
that enters the skin) will be single use only. The receiver, if used, is a hand- held devi ce. The [ADDRESS_1121383] approved these devices 367 
for single use and that by [CONTACT_28040], bloodborne pathogens (i.e. Hepatitis 368 
B) may be spread through the use of multiple users. 369 
The study insulin pump is labeled for single -patient use. During the study, this device may be 370 
reused after cleaning adhering to a hospi[INVESTIGATOR_307] -approved cleaning procedure. All infusion set 371 
equipment will be single patient use only (infusion set insertion kits, tubing, cartridges etc.)  372 
Participants will be info rmed that FDA or relevant national authorities typi[INVESTIGATOR_418072] 373 
pump device for single use and that by [CONTACT_28040], bloodborne pathogens 374 
(i.e. Hepatitis B) may be spread through the use of multiple users. 375 
The study blood glucose meter and blood ketone meter are labeled for single -patient use. 376 
During the study, only one person can use each device as there are rare risks that bloodborne 377 
pathogens (i.e. Hepatitis B) may be spread through the use of multiple users. 378 
[IP_ADDRESS] Questionna ires and Focus Groups  [ADDRESS_1121384] been uncommon. 385 
[IP_ADDRESS] Other Risks  386 
Some participants may develop skin irritation or allergic reactions to the adhesives used to secure 387 
the CGM, or to secure the insulin infusion sets for the continuous subcutaneous insulin infusion.  388 
If these reactions occur, different adhesives or “under -tapi[INVESTIGATOR_007]” (such as with IV 3000, Tegaderm, 389 
etc.) will be tried, sites will be rotated frequently, and a mild topi[INVESTIGATOR_91101] 390 
medication may be required. 391 
Whenever the skin is broken there is the possibility of an infection.  The CGM and pump infusion 392 
sites are inserted under the skin.  It is possible that any part that is inserted under the skin may 393 
 
 
 PEDAP
 PROTOCOL V 11.0  CLEAN  PAGE 25 OF 84 
 cause an infection.  These occur very infrequently, but, if an infection was to occur, oral and/or 394 
topi[INVESTIGATOR_27996].  The risk of skin problems could be greater if you use a sensor for 395 
longer than it is supposed to be used.  Therefore, participants  (and parents)  will be carefully 396 
instructed about proper use of the sensor. 397 
Data downloaded from the CGM, pump, and the home glucose and ketone meter will be collected 398 
for the study as measures of diabetes self -management behaviors.  Some people 399 
may be uncomfortable with the researchers' having such detailed information about their daily 400 
diabetes habits.  401 
 
 402 
One purpose of this research is to reduce the frequency of hypoglycemia and severe hypoglycemic 403 
events. Hypoglycemia is the number one fear of many individuals and families with someone who 404 
has type 1 diabetes and this fear often prevents optimal glycemic control.  405 
It is expected that this protocol will yield increased knowledge about using an automated 406 
closed -loop system  to control the glucose level and is intended to develop data to support future 407 
device approval  in the age group studied. The individual participant may not benefit from study 408 
participation.  409 
 
 410 
Based on the facts that (1) children with diabetes experience mild hypoglycemia and 411 
hyperglycemia frequently as a consequence of the disease and its management, (2) the s tudy 412 
intervention involves periodic automated insulin dosing that may reduce the likelihood of 413 
hypoglycemia, and periodic automated attenuation of insulin delivery that may reduce the 414 
likelihood of hyperglycemia, (3) if any, hypo and/or hyperglycemia occur , mitigations are in place, [ADDRESS_1121385] been tested in prior studies using the investigational device system in the home setting, 416 
that limit the likelihood of excessive insulin dosing or prolonged withdrawal of insulin, and (4) [ADDRESS_1121386] their origin in the Declaration of Helsinki, with the 425 
protocol described herein, and with the standards of Good Clinical Practice (GCP). [ADDRESS_1121387] that the closed loop 429 
system is experimental in the population under study.  Therefore, an investigational  device 430 
 
 
 PEDAP
 PROTOCOL V 11.0  CLEAN  PAGE 26 OF 84 
 exemption (IDE) from the U.S. Food and Drug Administration (FDA) is required to conduct the 431 
study. 432 
 
 
 PEDAP
 PROTOCOL V 11.0  CLEAN  PAGE 27 OF 84 
 Chapter 2:  Study Enrollment and Screening  433 
 Participant Recruitment and Enrollment  434 
Enrollment will proceed with the goal of having 10 2 participants randomized.  A maximum of 150 435 
individuals may be enrolled into screening for the study in order to achieve this goal. 436 
Study participants will be recruited at ~[ADDRESS_1121388] the following minimum numbers of participants 440 
complete the trial in the specified subgroups at the time of enrollment: 441 
• Approximately two -thirds of the participants with most recent available HbA1c ≥  7.5% 442 
• Approximately 30 participants in the age range ≥ 24 months to <48 months 443 
• At le ast 20% of participants who are on multiple daily injections (MDI) rather than pump 444 
 
 445 
Potential eligibility may be assessed as part of a routine -care examination.  Before completing any 446 
procedures or collecting any data that are not part of usual care, electronic informed consent will 447 
be obtained. 448 
A parent/legal guardian (referred to subsequently as “parent”) will be provided with the Informed 449 
Consent Form to read and will be given the opportunity to ask questions  either via 450 
phone/videoconference or by [CONTACT_65056]. If the parent and child are interested in the study, the 451 
investigator will schedule a virtual or in- person visit to discuss study, and if the parent and child 452 
agree to participate, the Informed Consent Form will be electronically signed through the JCHR 453 
website .  A copy of the electronically signed consent form can be printed by  [CONTACT_810860] 454 
copy will be printed by [CONTACT_468508]’s study record. [ADDRESS_1121389] 6 months  467 
2. Familiarity a nd use of a carbohydrate ratio for meal boluses. 468 
3. Age ≥ 2 and <6 years  old 469 
4. Living with one or more parent/legal guardian knowledgeable about emergency procedures for [ADDRESS_1121390] emergency services and study staff . 471 
5. Investigator has confidence that the parent can successfully operate all study devices and is 472 
capable of adhering to the protocol 473 
6. Willingness to switch to lispro (Humalog) or aspart (Novolog) if not using already, and to use 474 
no other insulin besides lispro (Humalog) or aspart (Novolog) during the study for participants 475 
using a study-provided Tandem pump during the study. 476 
• Study will not be providing insulin; therefore, participants will need to have access to 477 
either lispro or aspart 478 
7. Total daily insul in dose (TDD) at least 5 U/day  [ADDRESS_1121391] 20 lbs 480 
9. Willingness not to start any new non- insulin glucose -lowering agent during the course of the 481 
trial ( see section 2.3) 482 
10. Participant and parent(s)/guardian(s) willingness to participate in all training sessions as 483 
directed by [CONTACT_464].  484 
11. Parent/guardian proficient in reading and writing English 485 
12. Live in the [LOCATION_002], with no plans to move outside the [LOCATION_002] during the study 486 
period 487 
 Participant Exclusion Criteria  488 
Individuals meeting any of the following exclusion criteria at baseline will be excluded from study 489 
participation.  490 
1. Concurrent use of any non- insulin glucose -lowering agent (including GLP -1 agonists, Symlin, 491 
DPP-4 inhibitors, SGLT-2 inhibitors, sulfonylureas). 492 
2. Hemophilia or any other bleeding disorder 493 
3. History of >[ADDRESS_1121392] 3 494 
months 495 
4. History of >[ADDRESS_1121393] 8 weeks   501 
9. Known, ongoing  adhesive intolerance 502 
10. Plans to receive blood transfusions or erythropoietin injections during the course of the study 503 
11. A condition, which in the opi[INVESTIGATOR_66678], would put the participant or 504 
study at risk (specified in the study procedure  manual) ; the investigator will take into account 505 
the participant’s HbA1c level, compliance with current diabetes management, and prior acute [ADDRESS_1121394] of employment who is also directly involved in 513 
conducting the clinical trial (as a study investigator, coordinator, etc.); or having a first -degree 514 
relative who is directly involved in conducting the clinical trial 515 
 Eligibility Assessment and Baseline Data Collection  516 
Potential participants will be evaluated for study eligibility through the elicitation of a medical 517 
history and local laboratory testing as needed in the judgment of the investigator (as part of usual 518 
care).  519 
The screening visit and subsequent scheduled study visits may be conducted virtually via 520 
videoconference at the discretion of the study investigator, for example due to institutional 521 
restrictions or the participant or investigator’s preference for a remote visit. Study staff will [ADDRESS_1121395] to the participant’s diabetes history, current diabetes management, other past and current [ADDRESS_1121396] and current medications, and drug all ergies .   529 
 Screening Testing and Procedures  530 
At the Screening Visit the following procedures will be performed: 531 
• Informed consent process 532 
• Assessment of eligibility  533 
• Contact [CONTACT_3031] (retained at the clinical center and not entered into study database)  534 
• Demog raphics (date of birth, sex, race and ethnicity) 535 
 
 
 PEDAP
 PROTOCOL V 11.0  CLEAN  PAGE 30 OF 84 
 • Measurement of height/weight 536 
o If the visit is conducted virtually, a verbal report of the participant’s weight and [ADDRESS_1121397] a scale at home.  539 
• Determination of most recent HbA1c level from  medical records or verbal report  540 
• Participants ’ parents  will complete a set of baseline questionnaires, described in 541 
section 9.2. 542 
 Screen Failures  543 
Individuals who do not initially meet study eligibility requirements may be rescreened at a later 544 
date per investigator discretion. 545 
 
 
 PEDAP
 PROTOCOL V 11.0  CLEAN  PAGE 31 OF 84 
 Chapter 3:  CGM Run- In Phase  [ADDRESS_1121398] begin (supplies shipped) within 3 days of completion of the Screening visit. The 548 
purpose of this CGM run-in phase  is to 1) assess compliance with study procedures  and 2) to [ADDRESS_1121399] readings captured 553 
on fewer  than 11 out of the previous 14 days prior to time of enrollment , will be required to 554 
participate in the CGM run -in phase. 555 
Participants and their parent(s) will receive training on the study CGM as detailed below. This will 556 
be an unblinded use of the study CGM.  557 
 Initiation of CGM  558 
Study CGM supplies will be provided to the participant  either in -person at the clinic, or via 559 
deliv ery by [CONTACT_11174] (personal delivery, overnight shipment, etc.).   [ADDRESS_1121400] been received, the participant  and parent  will be instructed to use the study 561 
CGM on a daily basis. Participants using a personal CGM prior to the study will discontinue the 562 
personal CGM beginning in this period. 563 
 
 564 
CGM t raining (in-person or via videoconference) will be provided by a qualified trainer  to 565 
participants not currently using a personal CGM identical to the study CGM as to how to use it in 566 
real-time to make management decisions and how to review the data after an upload for 567 
retrospective review. The participating child will participate in training sessions to the degree 568 
judged appropriate by [CONTACT_810861]. CGM training will include: 569 
• Instruction on how to insert the sensor and transmitter, including observation/supervision 570 
of placement of a sensor  571 
• Instruction on how to calibrate the CGM unit, if needed  572 
• Guidance on accessing  the CGM trace, either through a manufacturer -provided software 573 
app or via a study- provided CGM receiver unit,  or via a personal insulin pump if 574 
participants  use a pump that integrates with the study CGM  575 
• Parents will be asked to perform fingerstick blood glucose measur ements in accordance 576 
with the labeling of the study CGM device 577 
A copy of the study CGM user’s guide will be provided to the participant’s parents. 578 
 
 
 PEDAP
 PROTOCOL V 11.0  CLEAN  PAGE 32 OF 84 
 
 Blood G lucose and K etone T esting  579 
Participants will receive supplies for blood glucose and ketone testing. 580 
• Blood glucose testing [ADDRESS_1121401] 582 
control solution to perform quality control (QC) testing at home per manufacturer 583 
guidelines. 584 
o All study blood glucose meters will be QC tested with control solution if available prior to 585 
dispensation and during all office visits.  A tested meter will not be used in a study if it 586 
does not read within the target range at each concentration per manufacturer labeling.   587 
o Participants will be reminded to use the study blood glucose meter for all fingerstick BGs 588 
during the study. 589 
o Participants will be given guidelines for treatment of low or high blood glucose. 590 
• Blood ketone testing [ADDRESS_1121402] control 592 
solution to perform QC testing at home per manufacturer guidelines, and 593 
software/hardware needed to download meter datafiles. 594 
o All study blood ketone meters will be QC tested with control solution if available prior to 595 
dispensation and dur ing all office visits.  A tested meter will not be used in a study if it 596 
does not read within the target range at each concentration per manufacturer labeling.  597 
o Participants will be instructed to perform blood ketone testing as described in section  7.1.6. 598 
o Participants will be given guidelines for treatment of elevated blood ketones 599 
• Participants will be required to have glucagon at home. Participants who currently do not have 600 
one will be given a prescription for glucagon (either emergency kit or nasal glucagon per 601 
investigator discretion for participants over 4 years of age). [ADDRESS_1121403] a follow -up visit or videoconference  approximately 14 days after 604 
initiation of the run -in phase to  assess progress or successful completion of the phase.  If needed, 605 
one or more interim visits or videoconference/ phone contacts may occur to assist the participant 606 
with any CGM  use issues. P rocedures will include downloading of the study CGM data and the 607 
following: [ADDRESS_1121404] 11 out of the prior 14 days 609 
Assessment of skin reaction in areas where a CGM sensor was worn or other safety issues 610 
associated with CGM use 611 
Assessment of eligibility to continue to the randomized control trial ( RCT ) phase of the study 612 
 613 
 
 
 PEDAP
 PROTOCOL V 11.0  CLEAN  PAGE 33 OF 84 
 Participants Using a Personal CGM at Enrollment 614 
Participants who had currently been using a personal CGM at the time of enrollment (but did not 615 
meet requirements to skip run- in) and satisfy the CGM use criteria above without any major  safety 616 
issues and otherwise meet study eligibility requirements can be randomized .  617 
Participants who fail to meet the minimum CGM use requirement, or who the investigator believes 618 
may benefit from an extension of the CGM run- in period, may at the investigator’s discretion be [ADDRESS_1121405] a follow -up visit or videoconference  630 
approximately 14 days for a second follow -up visit with the same visit procedures as described 631 
above. 632 
Participants who fail to meet the minimum CGM use requirement  at the second follow -up, or who 633 
the investigator believes may benefit from a  further extension of the CGM run- in period, may at 634 
the investigator’s discretion be allowed to continue CGM run- in for one additional [ADDRESS_1121406] a follow-up visit or videoconference approximately 14 days after the 636 
second follow-up visit for a reassessment using the same procedures as described above.  637 
Participants who do not meet CGM use requirements after three 2 -week  periods of CGM run- in or 638 
otherwise fail to meet study eligibility requirements will be withdrawn from the study.  639 
 Optimization of Insulin Therap y 640 
Data will be obtained from CGM and/or pump downloads prior to  CGM run -in review contact s. 641 
Adjustments to pump settings (basal rates, correction factor, insulin- to-carbohydrate ratio, etc.) or 642 
injection strategies will be made in response to major trends observed in the CGM data, with 643 
flexibility for clinicians to adhere to guidelines and prac tices established at each individual practice 644 
rather than a fixed set of heuristics for all clinical centers . 645 
 
 
 PEDAP
 PROTOCOL V 11.0  CLEAN  PAGE 34 OF 84 
 Chapter 4:  Randomization Visit  646 
 Visit  Timing  647 
The visit, which may be in- clinic or virtual,  may occur on the same day as the Screening or Run- 648 
in Review Visit, or on a subsequent day. If deferred, the randomization visit should occur no more 649 
than 14 days after successful completion of the run- in phase  or within 14 days of screening if run- 650 
in is skipped. 651 
 
 652 
Eligible participants will b e randomly assigned to one of two treatment groups in a 2:1 ratio: 653 
1. Control- IQ Closed -Loop Control ( CLC ) Group  [ADDRESS_1121407] C are (SC) Group  655 
The participant’s randomization group assignment is determined by [CONTACT_12550] a Randomization [ADDRESS_1121408] not randomize a 660 
participant until he/she is convinced that the participant/parent will accept assignment to either [ADDRESS_1121409] for in analysis than will clinical center . 665 
 
 666 
A capi[INVESTIGATOR_810857]1c determination . Capi[INVESTIGATOR_810858] 667 
supplies will be provided to the participant within 3 days of randomization. This may occur either 668 
in-person at the clinic, or via delivery by [CONTACT_11174] (personal delivery, overnight shipment, etc.).   669 
 
 
 PEDAP
 PROTOCOL V 11.0  CLEAN  PAGE 35 OF 84 
 Chapter 5:  Main Study Procedures  [ADDRESS_1121410] period, visits and contacts will be scheduled as outlined in Table 3 below: 672 
Table 3: RCT Visit and Phone Contact [CONTACT_263219]  673 
Target Day/Week  Contact [CONTACT_39764]1 Target/ Allowable Window  
(around Target Day/Week)  
3 days2 VC/P  ± 2 days  
1 week  P ± 2 days  
2 weeks  VC/V ± 4 days  
6 weeks  VC/V ± 7 days  
10 weeks  P ± 7 days  
13 weeks  VC/V ± [ADDRESS_1121411] Types are defined as Clinic Visit (V), Videoconference (VC), or Phone call (P); Phone calls may be replaced by 674 
Videoconferences or Clinic Visits and Videoconferences may be replaced by [CONTACT_810862]  675 
2 Only for participants on MDI at enrollment assigned to the CLC  group ; timing will be with respect to the start of home use of [ADDRESS_1121412] 677 
Additional contacts or visits may occur as needed. 678 
 CGM Initiation and Training  679 
Participants who skipped CGM run-in will be provided with study CGM supplies and training as 680 
described in section 3.2 and instructed to use the study CGM on a daily basis. Participants 681 
currently using a personal CGM identical to the study CGM may sk ip the training. 682 
Provision of CGM supplies and training should be completed  within 3 days of randomization. 683 
 Procedures for the CLC Group  684 
The study pump, associated supplies , and training will be provided to participants assigned to the 685 
CLC group within 3 days of randomization. Dispensation of supplies may occur either in -person 686 
at the clinic, or via delivery by [CONTACT_11174] (personal delivery, overnight shipment, etc.). 687 
 
 688 
Parents of participants will rec eive study pump training by a qualified trainer. The participating 689 
child will participate in training sessions to the degree judged appropriate by [CONTACT_74339] 690 
trainer.  Pump training (in -person or via videoconference) will be provided by a qualified trainer 691 
to all CLC Group participants. 692 
Parents  will be fully instructed on the study insulin pump. The trainer will discuss differences from 693 
the participant’s  personal pump, if applicable, in important aspects such as calculation of insulin [ADDRESS_1121413] and correction boluses  and optional additional topi[INVESTIGATOR_20188] : infusion site initiation, 695 
 
 
 PEDAP
 PROTOCOL V 11.0  CLEAN  PAGE 36 OF 84 
 cartridge/priming procedures, setting up the pump, charging the pump, navigation through menus, [ADDRESS_1121414] t:slim X2 training if they 700 
are not alre ady using the t:slim X2 bolus calculator. Parent/guardians with prior 701 
education/experience with using this bolus calculator will be offered refresher training. 702 
• The study team will assist the parent  in study pump infusion site initiation and will start 703 
the participant on the study pump. The study pump will be programmed with the 704 
participant’s usual basal rates and pump parameters , if applicable. The participant’s 705 
personal pump, if any, will be removed. 706 
• The parent will be supervised with the study pump during at least one meal or snack bolus 707 
to ensure participant understanding of the pump features. 708 
• The parent  will be encouraged to review the literature provided with the pump and infusion 709 
sets after the training is completed.  710 
• The parent will be trained on severe hypoglycemia emergency procedures including 711 
removal of the study pump and administration of glucagon. 712 
Pump training specific to the Control-IQ Technology functions will include: 713 
• How to turn on and off Control-IQ technology. 714 
• How to understand when Control- IQ is increasing or decreasing basal rates.  715 
• How to administer a meal or correction bolus es 716 
• What to do when exercising while using the system 717 
• How to enable the sleep function and set the sleep schedule 718 
• The parent will be assessed for understanding of the system interface and how to react to 719 
safety/alert messages.  720 
The parent  will be given a User Guide as a reference.  721 
 
 722 
For MDI participants being started on the study pump, a n initial basal insulin profile will be 723 
customized on a per -participant basis. Total daily insulin dose will be reduced by [CONTACT_3450] 724 
20% as a general rule, with a recommended method outlined in a separate procedures’ manual. 725 
Further adjustments to tota l daily dose (TDD) and intraday basal rate profile may be made during 726 
the initial 2 -week use period . 727 
Participants and parent(s) will complete training on the study pump as described above, with  728 
additional emphasis on topi[INVESTIGATOR_468506], suc h as infusion site initiation, 729 
cartridge/priming procedures, setting up the pump, charging the pump, navigation [ADDRESS_1121415] the participant/parent  in study pump infusion site i nitiation and will start 732 
the participant on the study pump. The study pump will be programmed with the participant’s 733 
insulin requirements. 734 
 
 735 
The participant/parent  will be instructed to use the system in closed -loop mode except if insul in is 736 
delivered by [CONTACT_3451] (e.g. injection of subcutaneous insulin via 737 
syringe in the event of infusion site failure). If insulin is delivered by [CONTACT_418091] [ADDRESS_1121416] study staff if the participating child has illness with 740 
an elevated temperature >101.5 degrees Fahrenheit (38.6 degrees Celsius), other periods of [ADDRESS_1121417] is required and will make arrangements 751 
with the parent  for the contacts.  If the parent cannot be reached, the participant’s other contact [ADDRESS_1121418], that the parent  is familiar with the function s/features/tasks addressed 757 
during the training. 758 
Parents  will be provided Hypoglycemia, Hyperglycemia and Ketone Guidelines ( section 8.2) for 759 
when their glucose levels are >300 mg/dL for more than 90 minutes  or >400 mg/dL at any time or 760 
<70 mg/dL or ketones ≥ 1.0 mmol/L.  761 
 
 762 
After training on the study system has been completed, participants will proceed with home use 763 
(meaning free-living use at school, home, etc.) of the study pump. [ADDRESS_1121419] an every 4-week  basis throughout the remainder 770 
of the study. 771 
 
 772 
For participants who were on MDI at the time of enrollment, study staff will perform a phone call 773 
or videoconference with the parent within 3 (± 2) days  following initiation of study pump use. 774 
The following will occur: 775 
• Assessment of compliance with study device use by [CONTACT_66706] 776 
• Assessment of adverse events, adverse device effects, and device issues  777 
• Study staff will answer any questions related to device use and follow the procedure for 778 
insulin pump optimization described above using the study CGM available data from the 779 
previous two weeks.  780 
 
 781 
Study staff will perform a phone call /videoconference with the parent  within 7 (±2) days  following 782 
randomization. 783 
The following will occur: 784 
• Assessment of compliance with study device use by [CONTACT_810863] 785 
• Assessment of adverse events, adverse device effects, and device issues  786 
• Study staff will answer any questions related to device use and follow the procedure for [ADDRESS_1121420] a follow-up visit 14 (±4) days from the date of randomization. 791 
The parent  will be offered review training to address any questions on the use of the study device 792 
including meal bolus strategies and strategies related to pump use and exercise. 793 
The following will occur: 794 
• Assessment of compliance with study device use by [CONTACT_66706]  795 
• Assessment of adverse events, adverse device effects, and device issues  796 
• Study staff will answer any questions related to device use and follow the procedure for 797 
insulin pump optimization described above using the study CGM available data from the 798 
previous two weeks. 799 
 
 
 PEDAP
 PROTOCOL V 11.0  CLEAN  PAGE 39 OF 84 
 • At in -clinic visits, the blood glucose meter and study ketone meter will be downloaded and 800 
QC tested with control solution. 801 
 Procedures for the S C Group  802 
Participants in the S C group will continue to use their existing in sulin therapy (personal pump or 803 
MDI) for the treatment of their diabetes, in conjunction with use of  the study CGM, study blood 804 
glucose meter, and study ketone meter. 805 
If a participant is using a pump with a n LGS /PLGS  feature, he/she will be allowed to cont inue [ADDRESS_1121421]-party 809 
components for this purpose . 810 
 
 811 
Parents  will be instructed to upload /email data from the study CGM and study ketone m eter using [ADDRESS_1121422] below for 813 
clinician review.  Parents  will be provided with any software and hardware needed to perform 814 
these data uploads. 815 
 
 816 
Study staff will perform a phone call /videoconference with the participant 7(+2) days  following 817 
randomization. 818 
The following will occur: 819 
• Assessment of compliance with study device use by [CONTACT_66706] 820 
• Assessment of adverse events, adverse device effects, and device issues  821 
• Study staff will answer any questions related to device use [ADDRESS_1121423] a follow-up visit 14 (±4) days from the date of randomization. 824 
The parent  will be offered review training on the use of S C during the remainder of the study, 825 
including meal bolus strategies and strategies r elated to exercise.  826 
The following will occur: 827 
• Assessment of compliance with study device use by [CONTACT_66706] 828 
• Assessment of adverse events, adverse device effects, and device issues  829 
• Study staff will review uploaded CGM data, answer any questions related to device use, 830 
and provide any recommendations for insulin therapy adjustment. 831 
 
 
 PEDAP
 PROTOCOL V 11.0  CLEAN  PAGE 40 OF 84 
 • If visit is in -clinic, the study blood glucose meter and study ketone meter will be [ADDRESS_1121424] is required and will 838 
make arrangements with the parent  for the contacts.  If the parent cannot be reached, the 839 
participant’s other contact [CONTACT_810864] b e utilized, including the emergency contact. 840 
 
 841 
A follow- up in- clinic  visit will occur at  6 weeks ( ±7 days) . The following procedures  are 842 
performed in both groups, unless otherwise specified below: 843 
Assessment of compliance with study device use by [CONTACT_810865]  844 
Assessment of adverse events, adverse device effects, and device issues  845 
Download of device data (study system or personal pump and study CGM, study BG meter, study 846 
ketone meter) ; in the case of videoconferences, participants  will upload or email available data 847 
prior to the visit, including CGM, pump, and ketone meter , so that clinic staff can review and 848 
download the data 849 
 
 850 
A follow- up phone call or videoconference will occur at  10 weeks ( ±7 days). At the discretion of [ADDRESS_1121425] may be replaced by [CONTACT_28920]- clinic visit.  852 
The following procedures are performed in both treatment groups: 853 
• Review of available CGM , ketone meter, and/or system data to identify any safety issues 854 
associated with current insulin therapy  and diabetes management approach  855 
• Assessment of adverse events, adverse device effects, and device issues  856 
Additional phone contacts may be performed as needed. 857 
 
 858 
If needed for safety reasons at the criteria of the physician at each clinical center, optimization may 859 
be done via phone contacts , videoconferences, or in -clinic visits.  860 
Data will be obtained from CGM and/or pump downloads during the contact . Adjustments to pump 861 
settings (basal rates, correction factor, insulin- to-carbohydrate ratio, etc.) or injection strategies [ADDRESS_1121426] a 13- Week (±7 days) visit during which the following will occur: 867 
• Collection of a blood sample to send to the central laboratory for HbA1c determination. 868 
• Completion of questionnaires  869 
• Weight and height measurement s will be repeated 870 
• Assessment of adverse events, adverse device effects, and device issues  871 
• Download of device data (study system or  personal pump and study CGM, study BG meter, 872 
study ketone meter) as available  873 
 Early Termination Visit (If Applicable)  [ADDRESS_1121427] unscheduled visits during the study period if required for additional device 878 
training or other unanticipated needs per the study investigator discretion. 879 
  880 
 
 
 PEDAP
 PROTOCOL V 11.0  CLEAN  PAGE 42 OF 84 
 Chapter 6:  Extension Phase  Procedures   [ADDRESS_1121428] Schedule  891 
During the Extension period, visits and contacts will be scheduled as outlined in Table 4 below: 892 
Table 4: Extension Phase Visit and Phone Contact [CONTACT_263219]  893 
Target Day/Week1 Contact [CONTACT_810866] e2 Target/ Allowable Window  
(around Target Day/Week)  
13 weeks + 3 days  VC/P  ± 2 days  
14 weeks  P ± 2 days  
15 weeks  VC/V ± 4 days  
19 weeks  VC/V ± 7 days  
23 weeks  P ± 7 days  
26 weeks  VC/V ± 7 days  
1 The “13 weeks” and subsequent visit targets reflect a participant who had no delay between the [ADDRESS_1121429] Types are defined as Clinic Visit (V), Videoconference (VC), or Phone call (P); Phone calls may be replaced by [ADDRESS_1121430] period will switch to the updated version 905 
of the Control- IQ system and will r eceive training on its  new features.  This will occur either the 906 
same day as the 13 -Week visit or within 2 weeks of this visit.  907 
 
 
 PEDAP
 PROTOCOL V 11.0  CLEAN  PAGE 43 OF 84 
 
 Visits, Videoconferences, and Phone Calls for All Participants  908 
 
 909 
Study staff will perform a phone call or videoconference with the parent within 3  (±2) days  [ADDRESS_1121431] a phone call or videoconference at 14 Weeks ( ±2 days) . Procedures will [ADDRESS_1121432] a follow -up visit at 15 Weeks ( ±4 days). Procedures will mirror those 917 
descri bed in section 5.3.8 above. 918 
 
 919 
A follow-up in- clinic visit will occur at 19 weeks ( ±7 days). Procedures will mirror those 920 
described in section 5.5.1 above. 921 
 
 922 
A follow-up phone call will occur at 23 weeks (±7 days). Procedures will mirror those described 923 
in section 5.5.2 above. 924 
 
 925 
A follow-up in -clinic visit will occur at 2 6 weeks ( ±7 days). Procedures will mirror those [ADDRESS_1121433] unscheduled visits during the study period if required for additional device 939 
training or other unanticipated needs per the study investigator discretion. 940 
 
 
 PEDAP
 PROTOCOL V 11.0  CLEAN  PAGE 44 OF 84 
 
 Participant Acc ess to Study Device at Study Closure  941 
Participant s not continuing to the Extended Use period will return all investigational study devices 942 
and supplies (insulin pump, CGM and related supplies).  Participant s may keep the study ketone 943 
meter and study glucometer if these devices are not marked for investigational use only. 944 
  945 
 
 
 PEDAP
 PROTOCOL V 11.0  CLEAN  PAGE 45 OF 84 
 Chapter 7:  Extended Use Period Procedures   [ADDRESS_1121434] Schedule  957 
During the Extended Use period, visits and contacts will be scheduled as outlined in Table 5 958 
below: 959 
Table 5: Extended Use Period  Visit and Phone Contact [CONTACT_263219]  960 
Target Day/Week with 
respect to initiation  of 
Extended Use period  Contact [CONTACT_39764]1 Target/ Allowable Window  
(around Target Day/Week)  
0 days (Retraining) 2 VC/V N/A 
3 days2 VC/P ± 2 days  
1 week2 VC/P  ± 2 days 
13 weeks  VC/V ± 7 days  
26 weeks  VC/V ± 7 days  
Final Visit  VC/V N/A 
[ADDRESS_1121435] Types are defined as Clinic Visit (V), Videoconference (VC), or Phone call (P); Phone calls may be replaced by [ADDRESS_1121436] a visit to 969 
receive retrain ing on the study pump prior to re-initiation of study pump use. 970 
 
 
 PEDAP
 PROTOCOL V 11.0  CLEAN  PAGE 46 OF 84 
 The procedures described in section 5.3 above will be followed to re -initiate these participants on 971 
the study pump.   972 
 
 973 
Study staff will perform a phone call or videoconference with the parent within 3  (±2) days  [ADDRESS_1121437] a phone call or videoconference within 7 days (±2 days) following re- 978 
initiation of study pump use. Procedures will mirror those described in section 5.3.7 above. 979 
 Visits, Videoconferences, and Phone Calls for All Participants  980 
 
 981 
A follow -up in- clinic visit will occur 13 weeks ( ±7 days) after the start of the Extended Use period. 982 
The following procedures will be  performed in both groups: 983 
• Collection of a blood sample to send to the central laboratory for HbA1c determination  984 
• Assessment of compliance with study device use by [CONTACT_66706] 985 
• Assessment of adverse events, adverse device effects, and device issues  986 
• Download of device data (study system or personal pump and study CGM, study BG meter, 987 
study ketone meter); in the case of videoconferences, participants will upload or email 988 
available data prior to the visit, including CGM, pump, and ketone meter, so that clinic 989 
staff can review and download the data  990 
Every 13 weeks ( ±7 days) thereafter, another follow -up clinic visit will occur involving the same [ADDRESS_1121438] udy Device at Study Closure  1006 
Participant will return all investigational study devices and supplies (insulin pump, CGM and 1007 
related supplies) at study closure.  Participant may keep the study ketone meter and study 1008 
glucometer if these devices are not marked for investigational use only. 1009 
 
 
 PEDAP
 PROTOCOL V 11.0  CLEAN  PAGE 48 OF 84 
 Chapter 8:  Study Devices  1010 
 Description of the Investigational Device 1011 
 
 1012 
The study system will include the Tandem t:slim X2 with Control-IQ technology. [ADDRESS_1121439] once every 10 days.  1016 
 
 1017 
Blood glucose levels will be measured using the study’s  blood glucose meter (glucometer) and the 1018 
CGM device will be calibrated if needed using the study glucometer and strips in accordance with 1019 
the manufacturer’s labeling.  1020 
 
 1021 
Blood ketone levels will be measured using the Abbott Precision Xtra meter and strips in 1022 
accordance with the m anufacturer’s labeling.  The blood glucose meter component of the Precision [ADDRESS_1121440] Tandem Technical Support via the study 1048 
team.  1049 
 
 1050 
During the course of the study, participants will be permitted to change the CGM low glucose 1051 
threshold alert setting  on their device or mobile app, but will be instructed to choose a value no 1052 
less than 70 mg/dL. 1053 
The t:slim X2 with Control- IQ system will issue a  predictive hypoglycemia alert (Control- IQ Low 1054 
Alert) when the system predicts BG <70 mg/dL within the next 15 minutes (<80 mg/dL when 1055 
exercise mode is activated ). 1056 
If the participant receives a Control- IQ Low Alert , a message appears on the user interface ( UI) 1057 
that is accompanied by [CONTACT_66703]/or sound if not acknowledged by [CONTACT_941] [ADDRESS_1121441] blood sugar and treat with carbs. 1060 
 
 1061 
During the course of the study, participants will be permitted to change the CGM high glucose 1062 
threshold alert setting  on their device or mobile app, but will be instructed to choose a value no 1063 
greater than 300 mg/dL. 1064 
The t:slim X2 with Control- IQ system wi ll issue a predictive hyperglycemia alert (Control -IQ 1065 
High Alert) when the system has increased insulin delivery, but detects a CGM value above 200 1066 
mg/dL and does not predict the value will decrease in the next 30 minutes. 1067 
If the participant receives a Control -IQ High Alert , a message appears on the UI that is 1068 
accompanied by [CONTACT_66703]/or sound if not acknowledged by [CONTACT_30799] [ADDRESS_1121442] blood glucose. 1071 
If a participant’s CGM reading is >300 mg/dL for over 90 minutes  or ≥400 mg/dL at any point, or 1072 
if CGM reading is >250 mg/dL more than 3 hours after a meal, the participant  took correction 1073 
 
 
 PEDAP
 PROTOCOL V 11.0  CLEAN  PAGE 50 OF 84 
 insulin, and CGM didn’t decrease by [CONTACT_2669] 50 mg/dL , the participant will be instructed to take 1074 
the following steps: [ADDRESS_1121443] infusion site for problems 1076 
Perform a blood glucose meter check. 1077 
If the blood glucose is >300 mg/dL, check for blood ketones with the study ket one meter.  1078 
If the ketone level is ≥1.0 mmol/L, take correction insulin, change insulin (pump) infusion site and [ADDRESS_1121444] study staff. 1080 
If a participant administers correction insulin via insulin syringe, participants will be instructed to 1081 
turn Control- IQ off for approximately four hours. 1082 
 
 
 PEDAP
 PROTOCOL V 11.0  CLEAN  PAGE 51 OF 84 
 Chapter 9:  Testing Procedures , Questionnaires , and Focus Groups  1083 
 Laboratory Testing 1084 
 
 1085 
Performed at the Randomization visit, 13-W eek visit, and 26- Week visit  1086 
Blood samples will be sent to the central laboratory for sample analysis using an NGSP approved 1087 
method. 1088 
 Questionnaires  1089 
The q uestionnaires listed  below are completed by [CONTACT_3445] s’ parents at Screening , 13 w eeks, 1090 
and 26 weeks  for all participants  except as noted .  The questionnaires  will be family and age 1091 
appropriate and are described briefly below.  The procedures for administration are described in 1092 
the clinical center procedures manual. 1093 
Pediatric Quality of Life – Parent  1094 
Pediatric Inventory for Parents  1095 
INSPI[INVESTIGATOR_66681] – Parent  1096 
Pi[INVESTIGATOR_2272] (PSQI) – Parent  1097 
Fear of Hypoglycemia Survey- Parents  (HFS -P) 1098 
Hypoglycemia Confidence Scale (HCS)  1099 
System Usability Scale (SUS) (Closed -Loop participants only at 13 and 26 weeks) [ADDRESS_1121445] the extent to which their child experienced each of 32 problems 1104 
related to diabetes in the prior month.  1105 
Administration time is approximately 5 minutes.  1106 
 
 1107 
This is a widely -used, 42-item measure of parenting stress designed for parents of youth with 1108 
type 1 diabetes.  1109 
Administration time is approximately 6 minutes.  1110 
 
 1111 
The INSPI[INVESTIGATOR_21392] ( Insulin Delivery S ystems: Perceptions, I deas, Reflections and E xpectations) survey 1112 
was developed to assess various aspects of a user’s experience regarding automated insu lin 1113 
 
 
 PEDAP
 PROTOCOL V 11.0  CLEAN  PAGE 52 OF 84 
 delivery for both patients and family members. The surveys include various topi[INVESTIGATOR_418079] 1114 
patients with type 1 diabetes and their family members based upon >[ADDRESS_1121446] -assessment survey 1116 
both contain 19 items. Response options for all surveys include a 5- point Likert scale from strongly 1117 
agree to strongly disagree, along with an N/A option. 1118 
Administration time is approximately 5 minutes.  1119 
 
 1120 
An abbreviated 9-question version of the Pi[INVESTIGATOR_2272] (PSQI ), a validated tool 1121 
for assessing self -reported sleep quantity and quality, will be completed by [CONTACT_3654]. S even 1122 
component scores are derived, each scored 0 (no difficulty) to 3 (severe difficulty). The 1123 
component scores are summed to produce a global score (range 0 to 21). Higher scores indicate 1124 
worse sleep quality.  1125 
Administration time is approximately 3 minutes.  1126 
 
 1127 
The Hypoglycemia Fear Survey- Parent  is a validated tool of 25 items to assess parents’ anxiety 1128 
and behavior concerning possible hypoglycemia . Items are rated on a 5 -point Likert scale 1129 
(0=never, 4=always), with higher scores indicating higher fear of hypoglycemia.  1130 
Administration time is approximately 4 minutes.  1131 
 
 1132 
The scale comprises 8 items and measures confidence hypoglycemia can be treated or prevented 1133 
in various situations.  1134 
Administration time is approximately 3 minutes.  1135 
 
 1136 
The System Usability Scale (SUS) is a 10 -item questionnaire that measures the overall usability 1137 
of a system. It is a valid and reliable measure of the perceived usability of a sys tem and is 1138 
technology- agnostic. The questionnaire presents statements with five response options (anchoring 1139 
the options from strongly disagree to strongly agree) and asks users to rate their agreement to the 1140 
statements.  User scores are transformed into a composite score, from 0 to 100, and this score is 1141 
taken as an overall measure of the system’s usability; higher scores indicate better perceived [ADDRESS_1121447] the child participant attend 1151 
briefly to answer a few questions, this will be attempted.  1152 
Sessions will be audio- and video- taped and transcribed by a professional transcription service. 1153 
Otherwise, these recordings will not be shared for any non- study purposes. Transcriptions will use 1154 
a code for participants, such as “Participant 1”, and will not contain names or other identifiers of 1155 
participants.   1156 
 
 
 PEDAP
 PROTOCOL V 11.0  CLEAN  PAGE 54 OF 84 
 Chapter 10:  Unanticipated Problem, Adverse Event, and Device Issues  1157 
Reporting 1158 
 Unanticipated Problems  1159 
Site investigators will promptly report to the Coordinating Center on an eCRF all unanticipated 1160 
problems meeting the criteria below. Problems meeting IRB reporting requirements will be 1161 
reported to the IRB within 7 calendar days of the site becoming aware of the problem. For this 1162 
protocol, an unanticipated problem is an incident, experience, or outcome that meets all of the 1163 
following criteria:  1164 
• Unexpected (in  terms of nature, severity, or frequency) given (a) the research procedures 1165 
that are described in the protocol related documents, such as the IRB- approved research 1166 
protocol and informed consent document; and (b) the characteristics of the subject 1167 
population being studied 1168 
• Related or possibly related to participation in the research (possibly related means there is [ADDRESS_1121448] been caused 1170 
by [CONTACT_3459])  1171 
• Suggests that the research places participants or others at a greater risk of harm than was 1172 
previously known or recognized ( including physical, psychological, economic, or social 1173 
harm)  [ADDRESS_1121449] be 1177 
reported to the JCHR IRB within seven calendar days of recognition. The Director of the Human 1178 
Research Protection Program will report to the appropriate regulatory authorities if the IRB 1179 
determines that the event indeed meets the criteria of an Unanticipated Problem requiring 1180 
additional repor ting. 1181 
 Adverse Events  1182 
 
 1183 
Adverse Event (AE):  Any untoward medical occurrence in a study participant, irrespective of the 1184 
relationship between the adverse event and the device(s) under investigation. 1185 
Serious Adverse Event (SAE): Any untoward medical occurrence that: 1186 
Results in death. 1187 
Is life -threatening; (a non -life-threatening event which, had it been more severe, might have 1188 
become life -threatening, is not necessarily considered a serious adverse event). 1189 
Requires inpatient hospi[INVESTIGATOR_10240].  1190 
 
 
 PEDAP
 PROTOCOL V 11.0  CLEAN  PAGE 55 OF 84 
 Results in persistent or significant disability/incapacity or substantial disruption of the ability to [ADDRESS_1121450] normal life functions (sight threatening). [ADDRESS_1121451]. 1193 
Is considered a significant medical event by [CONTACT_13656] (e.g., may 1194 
jeopardize the participant or may require medical/surgical intervention to prevent one of the 1195 
outcomes listed above). [ADDRESS_1121452] (UADE):  Any serious adverse effect on health or safety or [ADDRESS_1121453], 1198 
problem, or death was not previously identified in nature, severity, or degree of incidence in the 1199 
investigational plan or application (including a supplementary plan or application), or any other 1200 
unanticipated serious problem associated with a device that relates to the rights, safety, or welfare 1201 
of participants (21 CFR 812.3(s)). [ADDRESS_1121454] (ADE):  Any untoward medical occurrence in a study par ticipant which the [ADDRESS_1121455] contributed (Note that an Adverse Event 1204 
Form is to be completed in addition to a Device Deficiency or Issue Form, unless excluded from 1205 
reporting as defined in section 10.3).  An event that occurs solely due to participant (i.e., user) 1206 
error in which the device functions properly generally will not be considered an ADE unless it is 1207 
determined that the instructions on the screen of the device or user manual (or similar training 1208 
materials) may have contributed to the event (note: the event may still meet criteria for reporting 1209 
as an adverse e vent). 1210 
Device Complaints and Malfunctions:  A device complication or complaint is something that 1211 
happens to a de vice or related to device performance, whereas an adverse event happens to a 1212 
participant.  A device complaint may occur independently from an AE, or along with an AE.  1213 
An AE may occur without a device complaint or there may be an AE related to a device com plaint.  1214 
A device malfunction is any failure of a device to meet its performance specifications or otherwise 1215 
perform as intended.  Performance specifications include all claims made in the labeling for the 1216 
device.  The intended performance of a device refers to the intended use for which the device is 1217 
labeled or marketed. (21 CFR 803.3).  Note: for reporting purposes, sites  will not be asked to [ADDRESS_1121456] medical occurrence that meets 1221 
one of the following criteria: 1222 
1. An SAE or an AE associated with a visit to a hospi[INVESTIGATOR_3409] 1223 
2. An ADE  as defined in section 10.2.1, unless excluded from reporting in section 10.3 1224 
3. An AE as defined in section 10.2.1 occurring in association with a study procedure 1225 
4. An AE as defined in section 10.2.1 not related to a device issue which leads to temporary or 1226 
permanent discontinuation of a study device 1227 
5. An AE as defined in section 10.2.1 that affects the participant’s ability to complete any study 1228 
procedures 1229 
 
 
 PEDAP
 PROTOCOL V 11.0  CLEAN  PAGE 56 OF 84 
 6. Hypoglycemia meeting the definition of severe hypoglycemia as defined below  1230 
7. Diabetic ketoacidosis (DKA) as defined below or in the absence of DKA, a hyperglycemic or [ADDRESS_1121457].  Skin reactions from sensor placement are 1234 
only reportable if severe and/or required treatment. 1235 
All reportable AEs —whether volunteered by [CONTACT_2299], discovered by [CONTACT_66708] [ADDRESS_1121458], or other means —will be [ADDRESS_1121459] is only reportable as an adverse event 1241 
when the following definition for severe hypoglycemia is met:  the event required assistance of 1242 
another person due to altered consciousness, and required another person to actively administer 1243 
carbohydrate, glucagon, or other resuscitative actions.  This means that the participant was 1244 
impaired cognitively to the point that he/she was unable to treat hi mself/herself, was unable to 1245 
verbalize his/ her needs, was incoherent, disoriented, and/or combative, or experienced seizure or [ADDRESS_1121460] is only reportable as an adverse 1255 
event when one of the following criteria is met:  1256 
the event involved DKA, as defined by [CONTACT_810867] (DCCT) and 1257 
described below  1258 
evaluation or treatment was obtained at a health care provider facility for an acute event involving 1259 
hyperglycemia or ketosis , or the participant contact[CONTACT_66711] 1260 
manage the hyperglycemia/ ketosis 1261 
blood ketone level ≥ 1.0 mmol/L, even if there was no communication with a health care provider 1262 
at the time of the event  1263 
Hyperglycemic events are classified as DKA if the following are present:  1264 
Symptoms such as polyuria, polydipsia, nausea, or vomiting; 1265 
 
 
 PEDAP
 PROTOCOL V 11.0  CLEAN  PAGE 57 OF 84 
 Serum ketones ≥ 1.5 mmol/L or large/moderate urine ketones; 1266 
Either arterial blood pH <7.30 or venous pH <7.24 or serum bicarbonate (or CO 2) <15; and 1267 
Treatment provided in a health care facility  1268 
When a hyperglycemia/ketotic qualifies as an SAE as defined in section 10.2.1, a 1269 
Hyperglycemia/DKA Form should be completed in addition to the Adverse Event Form. Events [ADDRESS_1121461] been caused by 1276 
the study device. 1277 
To ensure consistency of adverse event causality assessments, investigators should apply the 1278 
following general guideline when determining whether an adverse event is related: 1279 
Yes 1280 
There is a plausible temporal relationship b etween the onset of the adverse event and the study 1281 
intervention, and the adverse event cannot be readily explained by [CONTACT_2299]’s clinical state, 1282 
intercurrent illness, or concomitant therapi[INVESTIGATOR_014]; and/or the adverse event follows a known pattern of 1283 
response to the study intervention; and/or the adverse event abates or resolves upon discontinuation 1284 
of the study intervention or dose reduction and, if applicable, reappears upon re- challenge.  1285 
No 1286 
Evidence exists that the adverse event has an etiology other than the study intervention (e.g., 1287 
preexisting medical condition, underlying disease, intercurrent illness, or concomitant 1288 
medication); and/or the adverse event has no plausible temporal relationship to study intervention.  1289 
 
 1290 
The severity (intensity) of an adverse event will be rated on a three point scale: (1) mild, (2) 1291 
moderate, or (3) severe.  A severity assessment is a clinical determination of the intensity of an 1292 
event. Thus, a severe adverse event is not necessarily serious.  For example, itching for several 1293 
days may be rated as severe, but may not be clinically serious. 1294 
• MILD: Usually transient, requires no special treatment, and does not interfere with the 1295 
participant’s daily activities.  1296 
• MODERATE: Usually causes a lo w level of inconvenience, discomfort or concern to the 1297 
participant and may interfere with daily activities, but is usually ameliorated by [CONTACT_3469] 1298 
therapeutic measures and participant is able to continue in study. 1299 
 
 
 PEDAP
 PROTOCOL V 11.0  CLEAN  PAGE 58 OF 84 
 • SEVERE: Interrupts a participant’s usual dai ly activities, causes severe discomfort, may 1300 
cause discontinuation of study device, and generally requires systemic drug therapy or 1301 
other treatment.  1302 
 
 1303 
For a serious adverse event that is considered possibly related to study device, the Medical 1304 
Monitor will classify the event as unexpected if the nature, severity, or frequency of the event is 1305 
not consistent with known risk information. 1306 
 
 1307 
Adverse events will be coded using the MedDRA dictionary. To facilitate coding, the site  will 1308 
enter a preliminary MedDRA code which the Medical Monitor may accept or change (the Medical 1309 
Monitor’s MedDRA coding will be used for all reporting). The Medical Monitor will review the 1310 
investigator’s assessment of causality and may agree or disagree.   Both the investigator’s and 1311 
Medical Monitor’s assessments will be recorded.  The Medical Monitor will have the final say in 1312 
determining the causality as well as whether an event is classified as a serious adverse event and/or [ADDRESS_1121462] . 1314 
 
 1315 
The outcome of each reportable adverse event will be classified by [CONTACT_3470]: 1316 
RECOVERED/RESOLVED – The participant recovered from the AE/SAE without sequelae.  [ADDRESS_1121463] the AE/SAE stop date.  1318 
RECOVERED/R ESOLVED WITH SEQUELAE – The event persisted and had stabilized without [ADDRESS_1121464] the AE/SAE stop date. 1320 
FATAL – A fatal outcome is defined as the SAE that resulted in death.  Only the event that was 1321 
the cause of death should be reported as fatal.  AEs/SAEs that were ongoing at the time of death; 1322 
however, were not the cause of death, will be recorded as “resolved” at the time of death.  1323 
NOT RECOVERED/NOT RESOLVED (ONGOING) – An ongoing AE/SAE is defined as the 1324 
event was ongoing with an undetermined outcome. 1325 
o An ongoing outcome will require follow -up by [CONTACT_810868] 1326 
outcome of the AE/SAE. 1327 
o The outcome of an ongoing event at the time of death that was not the cause of death, 1328 
will be updated and recorded as “resolved” with the date of death recorded as the stop 1329 
date.  1330 
UNKNOWN – An unknown outcome is defined as an inability to access the participant or the 1331 
participant’s records to determine the outcome (for example, a participant that was lost to follow - 1332 
up). 1333 
If any reported adverse events are ongoing when a participant completes the study (or withdraws), [ADDRESS_1121465] of improvement or change, even after the par ticipant has completed all applicable study 1336 
visits/contacts. For all other adverse events, data collection will end at the time the participant 1337 
 
 
 PEDAP
 PROTOCOL V 11.0  CLEAN  PAGE 59 OF 84 
 completes the study. Note: participants should continue to receive appropriate medical care for an 1338 
adverse event  after their participation in the study ends. 1339 
 Reportable Device Issues  1340 
All UADEs and ADEs as defined in section 10.2.1  will be reported on both a device issue form 1341 
and AE form, except for skin reactions from CGM sensor placement or pump infusion set 1342 
placement that do not require pharmacologic treatment.  As noted in section 10.2.1, events that 1343 
occur due to participant (user) error generally will not require completion of a device issue form. 1344 
Such ‘errors’ could include improper use of an insulin pump or using a pump infusion set or [ADDRESS_1121466] not been met:  1349 
CGM sensor lasting fewer days than expected per manufacturer  1350 
CGM tape adherence issues  1351 
Battery lifespan deficiency due to inadequate charging or extensive wir eless communication  1352 
Intermittent device component disconnections/communication failures not requiring system 1353 
replacement or workaround/resolution not specified in user guide/manual. [ADDRESS_1121467] be reported to 1358 
the Coordinating Center within 24 hours of the site becoming aware of the event.  This can occur 1359 
via phone or email, or by [CONTACT_263240] 1360 
form if applicable. If the form is not initially completed, it should be competed as soon as 1361 
possible after there is sufficient information to evaluate the event. All othe r reportable ADEs and 1362 
other reportable AEs should be submitted by [CONTACT_498301] 7 days of the 1363 
site becoming aware of the event.  1364 
The Coordinating Center will notify all participating investigators of any adverse event that is 1365 
serious, related, and unexpected. Notification will be made within 10 working days after the 1366 
Coordinating Center becomes aware of the event. 1367 
Each principal investigator [INVESTIGATOR_3411]- related adverse events and 1368 
abiding by [CONTACT_66716]/her Institutional Review Board or [ADDRESS_1121468] report all serious, related adverse events within seven calendar 1370 
days. 1371 
Upon receipt of a qualifying event, the Sponsor will investigate the event to determine if a 1372 
UADE is confirmed, and if indicated, report the results of the investigation to all overseeing 1373 
IRBs, and the FDA within 10 working days of the Sponsor becoming aware of the UADE per 1374 
 
 
 PEDAP
 PROTOCOL V 11.0  CLEAN  PAGE 60 OF 84 
 21CFR 812.46(b) (2).  The Medical Monitor must determine if the UADE presents an [ADDRESS_1121469] receipt notice of the UADE.  1379 
Device malfunctions will be handled by [CONTACT_263243].  In the case 1380 
of a CGM transmitter or sensor device malfunction, informatio n will be forwarded to Dexcom by 1381 
the site personnel, to be handled by [CONTACT_468516]. 1382 
 Safety Oversight 1383 
The study Medical Monitor will review all adverse events and adverse device events that are 1384 
reported during the study.  SAEs typi[INVESTIGATOR_66684] 24 hours of reporting.  Other 1385 
AEs typi[INVESTIGATOR_3413] a weekly basis. Additionally, the Medical Monitor will review 1386 
compi[INVESTIGATOR_27985] (generally timed to the review of compi[INVESTIGATOR_120712] 1387 
by [CONTACT_4318]).  1388 
The Protocol Chair will be informed of all cases of severe hypoglycemia and DKA and the 1389 
Medical Monitor’s assessment of relationship to the study device; and informed of all reported [ADDRESS_1121470] (DSMB) will be informed of all cases of s evere [ADDRESS_1121471] 1396 
modifications to the study protocol or suspension or outright stoppage of the study if deemed 1397 
necessary based on the totality of safety data available. Details regarding DSMB review will be 1398 
documented in a separate DSMB document. 1399 
 Stoppi[INVESTIGATOR_2121]  1400 
 
 1401 
In the case of an unanticipated system malfunction resulting in a severe hypoglycemia or DKA 1402 
event (or a malfunction that could have led to severe hypoglycemia or DKA), use of the study 1403 
pump will be suspended while the problem is diagnosed. The UADE will be reported to the IRB, 1404 
DSMB, and FDA. After assessment of the problem and any correction, use of the closed -loop 1405 
functionality  will not be restarted until approval is received from the IRB, DSMB, and FDA. 1406 
In the absence of a device malfunction, use of the study pump by a participant will be 1407 
discontinued if any of the following occur:  1408 
The investigator believes it is unsafe for the participant to continue on the intervention.  This could 1409 
be due to the development of a new medical condition or worsening of an existing condition; or 1410 
participant behavior contrary to the indications for use of the device that impos es on the 1411 
participant’s safety  1412 
 
 
 PEDAP
 PROTOCOL V 11.0  CLEAN  PAGE 61 OF 84 
 The participant’s parent  requests that the treatment be stopped  [ADDRESS_1121472] to determination of cause and whether the occurrence of the event can be 1419 
attributed to use of the Control- IQ closed -loop feature.  1420 
An additional requirement for continued study pump use following a single DKA or severe 1421 
hypoglycemia event will be that (1) the site investigator believes that the event is explainable, 1422 
unlikely to recur, and that it is safe for the participant to continue to use the system and (2) the 1423 
Medical Monitor and DSMB concur. If either the Medical Monitor or DSMB determines that the 1424 
occurrence of the event indicates that it is not safe for the participant to continue to use the study 1425 
pump, use will be discontinued. 1426 
Even if the study device system is discontinued, the participant will be encouraged to remain in 1427 
the study through the final study visit 1428 
 
 1429 
In the case of an unanticipated system malfunction resulting in a severe hypoglycemia or severe 1430 
hyperglycemia event (as defined in section 10.2.4), use of the study pump will be suspended while 1431 
the problem is diagnosed. 1432 
In addition, study activities could be similarly suspended if the manufacturer of any constituent 1433 
study device requires stoppage of device use for safety reasons (e.g. product recall).  The affected [ADDRESS_1121473] suspension of study activities or stoppage of the study if deemed necessary based on 1442 
the totality of safety data available. 1443 
 
 
 PEDAP
 PROTOCOL V 11.0  CLEAN  PAGE 62 OF 84 
 Chapter 11:  Miscellaneous Considerations  1444 
 Drugs Used as Part of the Protocol 1445 
Participants will use lispro , aspart , or glusiline  rapid -acting insulin prescribed by [CONTACT_810869] 1446 
physician. 1447 
 Collection of Medical Conditions and Medications  1448 
Pre-Existing Condition: Any medical condition that is either present at screening, a chronic [ADDRESS_1121474] the participant’s health during the course of the 1450 
study (e.g., prior myocardial infarction or stroke). 1451 
Medical Conditions during the study:  In addition to conditions meeting the reporting 1452 
requirements for an adverse event or device issue as described above, the following medical 1453 
conditions should also be reported: (1) new diagnosis of a chronic disease (i.e., not present at the 1454 
time of enrollment), and (2) any medical condition that could affect the participant’s ability to [ADDRESS_1121475] an outcome assessment.  1456 
Medications: All medication for the treatment of chronic pre -existing conditions, medical 1457 
conditions (including medical conditions that do not require recording), and/or adverse events [ADDRESS_1121476] their person al 1465 
physician to change their prescribed personal insulin to lispro or aspart for the duration of the trial  1466 
in the case they are randomized to experimental arm . 1467 
Treatment with any non -insulin glucose -lowering agent (including GLP -1 agonists, Symlin, DPP - 1468 
4 inhibitors, SGLT -2 inhibitors, biguanides, sulfonylureas and naturaceuticals) will not be 1469 
permitted.  1470 
The investigational study devices (t:slim X2 insulin pump, study CGM systems) must be removed 1471 
before Magnetic Resonance Imaging (MRI), Computed Tomography ( CT) or diathermy treatment. [ADDRESS_1121477] a commercially available glucagon (or glucagon analog) 1480 
preparation for treatment as needed of severe hypoglycemia. 1481 
 Participant Compensation 1482 
Participant compensation will be specified in the informed consent form. 1483 
 Participant Withdrawal 1484 
Participation in the study is voluntary, and a participant may withdraw at any time.  For  participants 1485 
who withdraw, their data will be used up until the time of withdrawal.  1486 
 Confidentiality  1487 
For security and confidentiality purposes, participants will be assigned an identifier that will be 1488 
used instead of their name.  Protected health information gathered for this study will be shared 1489 
with the coordinating c enter, the Jaeb Center for Health Research in Tampa, FL.  De- identified 1490 
participant information may also be provided to research sites involved in the study. 1491 
 
 
 PEDAP
 PROTOCOL V 11.0  CLEAN  PAGE 64 OF 84 
 Chapter 12:  Statistical Consideration 1492 
 Statistical and Analytical Plans 1493 
The approach to sample size and statistical analyses are summarized below. A detailed statistical 1494 
analysis plan will be written and finalized prior to the completion of the study. 1495 
 Statistical Hypotheses  1496 
The primary outcome for this study is CGM- measured % in range 70 -180 mg/dL over a 13- week 1497 
period. The intervention will be considered effective if the Closed-Loop Control [CLC] is [ADDRESS_1121478] Care [ SC] using a statistical significance of α=0.05 and the model specified 1499 
below in Section 6 (i.e., p < 0.05). 1500 
The null/a lternative hypotheses are:  1501 
a. Null Hypothesis : There is no difference in mean CGM -measured % in range 70 -180 1502 
mg/dL over 13 weeks between SC  and CLC  1503 
b. Alternative Hypothesis : The mean CGM -measured % in range 70-180 mg/dL over [ADDRESS_1121479] 1507 
deviation (SD) for the primary outcome, time in range (TIR), to be 10%. A sample size of N=90 1508 
subjects (60 in the CLC arm and 30 in the SC  arm) there fore will give 90% power to detect a 7.5% [ADDRESS_1121480] and type 1 error of 5%. Accounting for potential attrition 1510 
rate of up to 10%, the total sample size for the PEDAP Study is estimated at N=102. 1511 
 1512 
The following table shows the  minimum detectable difference with a total sample size N=[ADDRESS_1121481] Deviation  Correlation  
with  
Baseline  Effective  
SD a Detectable  
Difference 
with N=90 b Outcome CLC  
(n=78)  SC 
(N=22)  Pooled  
(N=100)  
% >250 mg/dL c 5.5% 9.9% 6.5% 0.69 4.7% 3.4% 
Mean Glucose d 18 26 20 0.68 14 10 
HbA1c  0.8% 0.9% 0.8% 0.70 0.6% 0.4% 
% <70 mg/dL c 1.07% 1.13% 1.08% 0.61 0.86% 0.63% 
% <54 mg/dL c 0.23% 0.23% 0.23% 0.54 0.19% 0.14% 
a – After accounting for the baseline value as a covariate in the regression model.  1515 
b – With 90% power and two- sided type 1 error rate = 5%.  1516 
c – Outcomes with a skewed distribution winsorized at the 10th and 90th percentiles.  1517 
d – Units for mean glucose are mg/dL.  1518 
 
 
 PEDAP
 PROTOCOL V 11.0  CLEAN  PAGE 65 OF 84 
 
 Efficacy Outcome Measures  1519 
 
 1520 
• CGM -measured % in range 70 -180 mg/dL 1521 
 
 1522 
[IP_ADDRESS] Secondary Efficacy Endpoints Included in Hierarchical Analysis  1523 
The following secondary endpoints will be tested in a hierarchical fashion as described in 1524 
section  12.7.1. 1525 
• CGM -measured % above 250 mg/dL 1526 
• CGM -measured mean glucose  1527 
• HbA1c at 13 weeks 1528 
• CGM -measured % below 70 mg/dL  1529 
• CGM -measured % below 54 mg/dL 1530 
[IP_ADDRESS] Other Secondary Efficacy Endpoints  1531 
The following endpoints are considered exploratory. Type 1 error for these endpoints will be 1532 
controlled using the false discovery rate (FDR) instead of the familywise error rate (FWER).   1533 
CGM -Measured:  1534 
• % above 180 mg/dL 1535 
• % in range 70-140 mg/dL  1536 
• glucose variability measured with the coefficient of variation (CV) 1537 
• glucose variability measured with the standard deviation (SD) 1538 
• % <60 mg/dL 1539 
• low blood glucose index (LBGI)* 1540 
• hypoglycemic events ( defined as at least 15 consecutive minutes <54 mg/dL) 1541 
• hyperglycemic events ( defined as at least 90 consecutive min utes >300 mg/dL) 1542 
• % >300 mg/dL  1543 
• high blood glucose index (HBGI)* 1544 
• % in range 70- 180 mg/dL improvement from baseline to 13 weeks ≥5%  1545 
• % in range 70- 180 mg/dL improvement from baseline to 13 weeks ≥10%  1546 
• % time in range 70-180 mg/dL >70% and % time <70 mg/dL <4%  1547 
HbA1c: 1548 
• HbA1c <7.0% at 13 weeks 1549 
• HbA1c <7.5% at 13 weeks 1550 
• HbA1c improvement from baseline to 13 weeks >0.5% 1551 
• HbA1c improvement from baseline to 13 weeks >1.0% 1552 
• HbA1c relative improvement from baseline to 13 weeks >10% 1553 
 
 
 PEDAP
 PROTOCOL V 11.0  CLEAN  PAGE 66 OF 84 
 • HbA1c absolute improvement from baseline to 13 weeks >1.0% or HbA1c <7.0% at 13 1554 
weeks  1555 
Questionnaires 1556 
• PedsQL Diabetes Module – total score and 5 subscales:  1557 
o Diabetes  1558 
o Treatment I  1559 
o Treatment II  1560 
o Worry  1561 
o Communication  1562 
• Pediatric Inventory for Parents (PIP) 2 domains each with a total score and 4 subscales for 1563 
(5x2=10 difference scores)  1564 
o Frequency  1565 
 Total Score  1566 
 Communication  1567 
 Medical Care  1568 
 Role Function 1569 
 Emotional Functioning 1570 
o Difficulty  1571 
 Same total + 4 subscales as above for Frequency  1572 
• INSPI[INVESTIGATOR_21392] (CLC arm only) 1573 
• Pi[INVESTIGATOR_2272] (PSQI) global score 1574 
• Fear of Hypoglycemia Survey for Parents (HFS- P) – total score, 2 subscales and 4 factor 1575 
scores:  1576 
o Behavior  1577 
 Avoidance 1578 
 Maintain high BG 1579 
o Worry  1580 
 Helplessness  1581 
 Social consequences  1582 
 1583 
*Note that LBGI and HBGI will be calculated using all available CGM readings as described 1584 
below. Therefore, they may not be comparable to the same metrics calculated with SMBG data.  1585 
Other:  1586 
• Insulin 1587 
♦ Total daily insulin (units/kg) 1588 
♦ Percentage of total insulin delivered via basal  1589 
•  Weight and Body Mass Index (BMI) 1590 
 
 1591 
Randomization is preceded by 2-6 weeks of CGM run-in, which will be used in the calculation 1592 
of baseline CGM metrics. F or participants  who are eligible to skip the run-in, comparable 1593 
 
 
 PEDAP
 PROTOCOL V 11.0  CLEAN  PAGE 67 OF 84 
 amount of CGM data from their own sensors will be taken before randomization visit to 1594 
calculate baseline CGM metrics . 1595 
CGM data starting from randomization visit through the 13- week visit will be included in the 1596 
calculation of each CGM metric. Percentages in range 70 -180 mg/dL (and all other CGM- based 1597 
metrics) will be calculated giving equal weight to each CGM point for each participant. 1598 
 Analysis Datasets and Sensitivity Analyses 1599 
All analyses comparing the CLC arm with SC  arm will follow intention -to-treatment approach, 1600 
which means participants will be analyzed in the treatment arm assigned by [CONTACT_17628] 1601 
regardless of actual system use. All randomized participants will be included in the primary 1602 
analysis and secondary hierarchical analyses of CGM metrics. For other secondary outcomes, 1603 
only participants with non-missing outcome data will be included. 1604 
Safety outcomes will be reported for all enrolled participants, irrespective of whether the 1605 
participant was randomized or the study was completed. 1606 
 
 1607 
Per-protocol analyses will be performed for primary outcome and secondary hierarchical  1608 
outcomes only if >5% of participants will be excluded: 1609 
• CLC arm: Closed loop mode active for at least 80% of the time  1610 
• SC arm: CGM use for at least 80% of the time  [ADDRESS_1121482] a linear relationship with the outcome. In such a case, 1620 
categorization and/or transformation will be explored. [ADDRESS_1121483] to handle missing data. Our goal is to minimize the amount of 1628 
missing data so that the results will not be sensitive to which statistical method is used.  1629 
To that end, sensitivity analyses will be performed to explore whether results are similar for 1630 
primary analysis when using different methods. The following methods will be applied: 1631 
• Rubin’s multiple imputation with treatment group in the imputation model  1632 
• Available cases only  1633 
• Multiple imputation with pattern mixture model assuming the dropout trajectory of the 1634 
CLC group was that of the SC  group (Mallinckrodt and Clark, 2003) (3)  1635 
 Analysis of the Primary Efficacy Endpoint 1636 
Summary statistics (mean ± SD or median (quartiles)) will be reported by [CONTACT_21705] 1637 
CGM -measured % in range 70 -180 mg/dL at baseline, 13 weeks intervention and change from 1638 
baseline to 13 weeks. 1639 
CGM -measured % in range 70 -180 mg/dL between two treatment arms will be compared using a 1640 
linear mixed effects regression model while adjusting for baseline CGM- measured % in range 1641 
70-180 mg/dL, age, prior CGM and pump use, and clinical center (random effect). A point 1642 
estimate, 95% confidence interval and two- sided p- value will be reported for the treatment effect 1643 
based on the linear regression model and a 5% level will be used to declare statistical [ADDRESS_1121484] regression using M-estimation will be used instead. However, 1646 
previous experience suggests that the residual values for % time glucose in target range wi ll 1647 
follow an approximately normal distribution. Imbalances between groups in important covariates 1648 
are not expected to be of sufficient magnitude to produce confounding. However, the presence of 1649 
confounding will be evaluated in the sensitivity analyses by [CONTACT_810870] 1650 
associated with the outcome for which there is an imbalance between groups ( 12.5.2).  [ADDRESS_1121485] for the corresponding baseline metric, age, prior 1659 
CGM and pump use, and clinical center (random effect). 1660 
 
 1661 
To preserve the overall type 1 error for selected key secondary endpoints, a hierarchical testing 1662 
procedure will be used. If the primary analysis for time in range described above results in a 1663 
statistically significant result (p < 0.05),  then testing (similar to the model described above 1664 
for the primary outcome) will proceed to the next outcome metric in the following order: 1665 
 
 
 PEDAP
 PROTOCOL V 11.0  CLEAN  PAGE 69 OF 84 
 • CGM -measured % in range 70 -180 mg/dL (primary outcome) 1666 
• CGM -measured % above 250 mg/dL 1667 
• CGM -measured mean glucose  1668 
• HbA1c at 13 weeks  1669 
• CGM -measured % below 70 mg/dL 1670 
• CGM -measured % below 54 mg/dL [ADDRESS_1121486] until a non- 1673 
significant result (p ≥ 0.05) is observed, or all six  variables have been tested. If a non- significant [ADDRESS_1121487] are not formally tested . 1676 
Regardless of the results of the hierarchical testing, summary statistics appropriate to the 1677 
distribution will be tabulated by [CONTACT_418098].  A 9 5% confidence [ADDRESS_1121488] failed to 1681 
reach statistical significance.  1682 
Analysis for each of the CGM metrics listed above for the hierarchical analysis will parallel the 1683 
analysis described for the primary outcome in Section 12.6. 1684 
HbA1c at 13 weeks will be compared between the two treatment arms using a linear model while 1685 
adjusting for baseline HbA1c, age, prior CGM and pump use, and clinical center (random 1686 
factor). Missing data will be handled using direct likelihood in a regression model including all 1687 
available central laboratory HbA1c measurements at baseline and 13 -week visits.  1688 
For all above analyses, regression diagnostics will be employed analogous to as described in 1689 
Section 12.6 for the primary outcome. 1690 
 
 1691 
For all other secondary endpoints, only participants with non- missing data will be included in 1692 
analyses (available cases method). Summary statistics (mean ± SD, median (IQR) or n (%)) 1693 
appropriate to the distribution will be tabulated for them at baseline, 13 weeks and for the 1694 
changes from baseline to 13 weeks. For continuous outcomes, linear regression models will be 1695 
used to compare the treatment effects while adjusting for corresponding baseline values (e.g., 1696 
baseline % in range 70 -140 mg/dL for comparing change in % in range 70-140 mg/dL from pre- [ADDRESS_1121489]-randomization period), age, prior CGM and pump [ADDRESS_1121490]. Comparisons of body weight and BMI will also be 1699 
adjusted for gender. 1700 
For CGM -measured hypoglycemia/hyperglycemia events, event rates per week will be compared [ADDRESS_1121491] for baseline 1706 
HbA1c (as a continuous factor), age, prior CGM and pump use as fixed effects, and clinical site [ADDRESS_1121492]. Similar analyses will be done for the binary CGM outcomes. 1708 
Questionnaires  1709 
For each questionnaire, mean ± SD or percentiles appropriate to the distribution will be given by 1710 
treatment group at baseline and 13 weeks. Group comparisons will be conducted for the total 1711 
score (mean score) and subscales from participant version and parent version separately using [ADDRESS_1121493]- treatment survey s will 1713 
only be administered to the CLC group at the 13-week visit, and thus the scores will only be 1714 
tabulated.  1715 
Focus Groups  1716 
Qualitative data from focus groups will be analyzed using NVIVO (release 11.2; QSR 1717 
International) to organize and manage the entire corpus of focus group data. Analysis begins [ADDRESS_1121494] -randomization 1731 
safety events will be reported.  Any pre- randomization adverse events will be tabulated separately 1732 
and will include any participants who were never randomized. 1733 
Safety analyses of the main study (randomized tri al phase) will include events  occurring on or [ADDRESS_1121495] event date (whichever is later).  1737 
For the following outcomes, the number of events will be tabulated by [CONTACT_1570]. F ormal 1738 
statistical comparisons (main study phase only) will be performed if there are enough events (at [ADDRESS_1121496] 5 events combin ed between the two treatment groups): 1740 
• Number of SH events and SH event rate per 100 person- years  1741 
 
 
 PEDAP
 PROTOCOL V 11.0  CLEAN  PAGE 71 OF 84 
 • Number of DKA events and DKA event rate per 100 person- years  1742 
• Other serious adverse events  1743 
• Any adverse event rate  1744 
• Number of calendar days with any ketone level ≥ 1.0 mmol/L (if ≥5 total calendar days 1745 
combined) 1746 
• Worsening of HbA1c from baseline to 13 weeks by >0.5% 1747 
• Investigational device related (intervention group only): 1748 
o Adverse device effects (ADE)  1749 
o Serious adverse device events (SADE)  1750 
o Unanticipated adverse device effects (UADE)  [ADDRESS_1121497] 5 total DKA events 1757 
among both treatment groups.  1758 
 1759 
 Intervention Adherence  1760 
The following tabulations and analyses will be performed by [CONTACT_418100] 1761 
intervention adherence for the study: 1762 
• Sensor use –percent time of use, overall for 13-week visit 1763 
For CLC arm only, the following will be tabulated to assess adherence: 1764 
• Closed loop system use–percent time of use, overall for 13-week visit 1765 
• % time in different operational modes - overall and by [CONTACT_810871]  1766 
 Protocol Adherence and Retention  1767 
The following tabulations and analyses will be performed by [CONTACT_418101] 1768 
adherence for the study: 1769 
• Number of protocol and procedural deviations  1770 
• Flow chart accounting for all enrolled participants up to randomization 1771 
• Flow chart of all randomized participants at  all scheduled visits and phone contacts post 1772 
treatment initiation  1773 
• Number of and reasons for unscheduled visits and phone calls 1774 
• Number of participants who stopped treatment and reasons 1775 
 Baseline Descriptive Statistics  1776 
Baseline demographic and clinical characteristics of the cohort of all randomized participants 1777 
will be summarized in a table using summary statistics appropriate to the distribution of each 1778 
variable. Descriptive statistics will be displayed by [CONTACT_66723]: 1779 
 
 
 PEDAP
 PROTOCOL V 11.0  CLEAN  PAGE 72 OF 84 
 • Age 1780 
• Sex 1781 
• Race/Eth nicity  1782 
• Parent’s income, education, and/or insurance status 1783 
• Diabetes duration  1784 
• Insulin method before enrollment (pump vs. MDI) 1785 
• CGM use before enrollment 1786 
• HbA1c  1787 
• BMI  % 1788 
• Participant -reported number of SH and DKA 12 months prior to the start of the study 1789 
• Baseline CGM metrics including: 1790 
• % in range 70-180 mg/dL 1791 
• % time > 180 mg/dL 1792 
• Mean glucose 1793 
• % time < 70 mg/dL  1794 
• % time < 54 mg/dL  1795 
 Device Issues  1796 
The following tabulations and analyses will be performed by [CONTACT_418103] 1797 
issues:  1798 
• Device malfunctions requiring study team contact [CONTACT_91120] 1799 
• Rate of different failure events and alarms per 24 hours recorded by [CONTACT_418104]- IQ system – [ADDRESS_1121498] prior to the completion of the extension phase. 1804 
In addition, the DSMB will review safety data at intervals, with no formal stoppi[INVESTIGATOR_004].  1805 
 Subgroup Analyses  1806 
In exploratory analyses, the primary outcome (time 70 -180 mg/dL), % time <70 mg/dL and HbA1c 1807 
at 13 weeks will be assessed separately in various subgroups. Subgroups will be defined according 1808 
to the baseline value of the factors, which will be noted in the SAP . Tests for interaction 1809 
with treatment group will be performed. 1810 
Interpretation of subgroup analyses will be viewed with caution, particularly in the absence of an 1811 
overall significant difference. For continuous variables, results will be displayed in subgroups 1812 
based on cutpoints although the analysis will utilize the variable as continuous. If there is 1813 
insufficient sample size in a given subgroup, the cutpoints for continuous measures may be 1814 
adjusted per the observed distribution of values. Cutpoint selection for display purpose s will be 1815 
made masked to the outcome data. 1816 
 
 
 PEDAP
 PROTOCOL V 11.0  CLEAN  PAGE 73 OF 84 
 
 Multiple Comparison/Multiplicity  1817 
Primary Analysis 1818 
Since there will be a single comparison for the primary outcome (CGM -measured % 70 -180 1819 
mg/dL), no adjustment is needed. 1820 
Secondary Hierarchical Analyses 1821 
The hierarchical testing procedure described above in section 12.7.1 will be used to control the 1822 
overall type 1 error for the primary outcome plus five key secondary outcomes identified above. 1823 
All Other Secondary Analyses 1824 
For comparison of all other efficacy endpoints, the false discovery rate will be controlled using the 1825 
adaptive Benjamini -Hochberg procedure (4). 1826 
P-values from safety analyses, sensitivity analyses, and per-protocol analyses will not be adjusted 1827 
for multiple comparisons. 1828 
 Exploratory Analyses 1829 
CGM Metrics  1830 
In addition to the analysis for the CGM -measured  endpoints described earlier, separate analyses 1831 
will be conducted for daytime and nighttime of the following metrics: 1832 
• % time in range 70- 180 mg/dL  1833 
• Mean glucose 1834 
• % above 180 mg/dL 1835 
• % below 70 mg/dL 1836 
• coefficient of variation  1837 
 1838 
Above selected CGM metrics also wil l be reported by [CONTACT_810872] 1839 
based on following criteria. No p -values will be calculated for following analyses.  1840 
• using only the CGM data when the closed-loop is active 1841 
 1842 
Additional Insulin Metrics 1843 
The following insulin metrics will be tabulated by [CONTACT_810873], 13 weeks and for 1844 
the changes from baseline to 13 weeks. No p- values will be calculated for these metrics.  1845 
• Total daily basal insulin (units/kg) 1846 
• Total daily bolus insulin (units/kg) 1847 
• Total daily manual bolus (units/kg) 1848 
• Total daily automated bolus (units/kg) 1849 
• Total daily short-acting injections for injection users 1850 
 1851 
 
 
 PEDAP
 PROTOCOL V 11.0  CLEAN  PAGE 74 OF 84 
 The following will be calculated for the CLC group in the 1-week prior to randomization and by 1852 
1-week follow-up periods from pump data only: 1853 
• Total daily insulin (units/kg) 1854 
• Total daily basal insulin (units/kg) 1855 
• Total daily bolus insulin (units/kg) 1856 
o Total daily manual bolus (units/kg) 1857 
o Total daily automated bolus (units/kg) 1858 
• Number of manual insulin doses per day 1859 
• Number of manual insulin doses with carb announcement per day [ADDRESS_1121499] baseline (pre-randomization), [ADDRESS_1121500] and extension (where both arms using CLC) phases. 1868 
Formal statistical comparisons between the two study phases (i.e., primary RCT and extension 1869 
phases) will be performed for key outcome measures including: 1870 
• CGM -measured % in range 70 -180 mg/dL 1871 
• CGM -measured % ab ove 250 mg/dL 1872 
• CGM -measured mean glucose  1873 
• HbA1c at 13 weeks 1874 
• CGM -measured % below 70 mg/dL 1875 
• CGM -measured % below 54 mg/dL 1876 
• PedsQL Diabetes Module – total score  1877 
• Pediatric Inventory for Parents (PIP) 1878 
 Frequency domain total score 1879 
 Difficulty domain total score  1880 
• INSPI[INVESTIGATOR_66681]  1881 
• Pi[INVESTIGATOR_2272] (PSQI) global score 1882 
• Fear of Hypoglycemia Survey for Parents (HFS- P) – total score  1883 
• Hypoglycemia Confidence Scale (HCS)  1884 
• System Usability Scale (SUS)  [ADDRESS_1121501] and extension phases a ccounting for the correlated data from repeated measures. Treatment 1887 
group will be a time dependent factor in this model. A point estimate and 95% confidence [ADDRESS_1121502] to one another. Safety analyses of the Extension Phase will 1890 
include events occurring on or after the Extension training visit until the end of the 26- Week visit 1891 
 
 
 PEDAP
 PROTOCOL V 11.0  CLEAN  PAGE 75 OF 84 
 or the end of Day 105 from the Extension training visit — whichever occurs first. Safety 1892 
outcomes will include those specified in section 12.8 with the exception of worsening of HbA1c. 1893 
Summary statistics appropriate to the distribution will be tabulated without any formal 1894 
comp arisons by [CONTACT_810874] 12.8. 1895 
 
 1896 
According to Chapter 14, during the extension phase, 30 – [ADDRESS_1121503] the Control- IQ system with meal bolus and exercise 1898 
challenges. The analyses for this ancillary study are specified in Section 14.5. Data collected 1899 
from the start of each of these challenges until 5:[ADDRESS_1121504] 1910 
event date (whichever is later).  Safety outcomes will include those specified in section 12.8 with 1911 
the exception of worsening of HbA 1c. 1912 
  1913 
 
 
 PEDAP
 PROTOCOL V 11.0  CLEAN  PAGE 76 OF 84 
 Chapter 13:  Data Collection and Monitoring  1914 
 Case Report Forms and Device Data  1915 
The main study data are collected on electronic case report forms (CRFs). When data are directly 1916 
collected in electronic case report forms, this will be considered the source data. For any data 1917 
points for which the eCRF is not considered source (e.g. lab results that are transcribed from a 1918 
printed report into the eCRF), the original source documentation must be maintained in the 1919 
participant’s study chart or medical record. This source must be readily verifiable against the [ADDRESS_1121505] be recorded (e.g., office note, visit record, 1922 
etc.).    [ADDRESS_1121506].  These documents should be retained for a longer 1933 
period, however, if required by [CONTACT_427].  No records will be destroyed without the written 1934 
consent of the sponsor, if applicable.  It is the responsibility of the sponsor to inform the 1935 
investigator when these documents no longer need to be retained. 1936 
 Quality Assurance and Monitoring  1937 
Designated personnel from the Coordinating Center will be responsible for maintaining quality 1938 
assurance (QA) and quality control (QC) systems to ensure that the clinic al portion of the trial is 1939 
conducted and data are generated, documented and reported in compliance with the protocol, 1940 
Good Clinical Practice (GCP) and the applicable regulatory requirements, as well as to ensure 1941 
that the rights and wellbeing of trial participants are protected and that the reported trial data are 1942 
accurate, complete, and verifiable.  Adverse events will be prioritized for monitoring. 1943 
A risk -based monitoring (RBM) plan will be developed and revised as needed during the course 1944 
of the study, consistent with the FDA “Guidance for Industry Oversight of Clinical 1945 
Investigations — A Risk -Based Approach to Monitoring” (August 2013).  Study conduct and 1946 
monitoring will conform with 21 Code of Federal Regulations (CFR) 812. This plan describes in [ADDRESS_1121507] importance for monitoring at the site are participant eligibility  and adverse 1950 
events.  Therefore, the RBM plan will focus on these areas.  As much as possible, remote 1951 
monitoring will be performed in real- time with on -site monitoring performed to evaluate the 1952 
verity and completeness of the key site data.  Elements of the RBM may include: 1953 
• Qualification assessment, training, and certification for sites and site personnel 1954 
• Oversight of Institutional Review Board (IRB) coverage and informed consent procedures 1955 
• Central (remote) data monitoring: validation of data entry, data edi ts/audit trail, protocol 1956 
review of entered data and edits, statistical monitoring, study closeout 1957 
• On-site monitoring (site visits): source data verification, site visit report 1958 
• Agent/Device accountability  1959 
• Communications with site staff  1960 
• Patient retention and  visit completion  1961 
• Quality control reports 1962 
• Management of noncompliance 1963 
• Documenting monitoring activities  1964 
• Adverse event reporting and monitoring [ADDRESS_1121508] access to all trial related  sites, source 1969 
data/documents, and reports for the purpose of monitoring and auditing by [CONTACT_456], and 1970 
inspection by [CONTACT_3482]. 1971 
 Protocol Deviations 1972 
A protocol deviation is any noncompliance with the clinical trial protocol, GCP, or procedure 1973 
requirements.  The noncompliance may be either on the part of the participant, the investigator, 1974 
or the study site staff.  As a result of deviations, corrective actions are to be developed by [CONTACT_779] 1975 
and implemented promptly. 1976 
The site PI/study staff is responsible for knowing and adhering to their IRB requirements.  Further 1977 
details about the handling of protocol deviations will be included in the monitoring plan. 1978 
 
 
 PEDAP
 PROTOCOL V 11.0  CLEAN  PAGE 78 OF 84 
 Chapter 14:  Ethics/Protection of Human Participants  [ADDRESS_1121509]  1980 
The investigator will ensure that this study is conducted in full conformity with Regulations for 1981 
the Protection of Human Participants of Research codified in 45 CFR Part 46, 21 CFR Part 50, 21 1982 
CFR Part 56, and/or the ICH E6. 1983 
 Institutional Review Boar ds 1984 
The protocol, informed consent form(s), recruitment materials, and all participant materials will [ADDRESS_1121510] be obtained before any participant is enrolled.  Any amendment to the protocol will 1987 
require review and approval by [CONTACT_3484].  All 1988 
changes to the consent form will be IRB approved; a determination will be made regarding whether 1989 
previously consented participants need to be re- consented.  1990 
 Informed Consent Process  1991 
 
 1992 
Informed consent is a process that is initiated prior to the individual’s agreeing to participate in 1993 
the study and continues throughout the individual’s study participation.  Extensive discussion of [ADDRESS_1121511] by [CONTACT_3486], their staff, 2010 
and the sponsor(s) and their agents.  This confidentiality is extended to cover testing of [ADDRESS_1121512] all documents and records 2017 
required to be maintained by [CONTACT_093], including but not limited to, medical records 2018 
(office, clinic, or hospi[INVESTIGATOR_307]) and pharmacy records for the participants in this study.  The clinical 2019 
study si te will permit access to such records.  2020 
The study participant’s contact [CONTACT_3487] 2021 
internal use during the study.  At the end of the study, all records will continue to be kept in a 2022 
secure location for as l ong a period as dictated by [CONTACT_3488], institutional policies, or 2023 
sponsor requirements. 2024 
Study participant research data, which is for purposes of statistical analysis and scientific reporting, 2025 
will be transmitted to and stored at the Jaeb Center for Health Research (JCHR) .  This will not 2026 
include the participant’s contact [CONTACT_1290], unless otherwise specified in the [ADDRESS_1121513] protected.  At the 2030 
end of the study, all study databases will be de -identified and archived at the JCHR  and the 2031 
University of Virginia Center for Diabetes Technology. 2032 
  2033 
 
 
 PEDAP
 PROTOCOL V 11.0  CLEAN  PAGE 80 OF 84 
 Chapter 15:  Ancillary Study to Test Control -IQ System with Meal [ADDRESS_1121514] these challenges. This 2054 
material will be reviewed with each participant.  2055 
During home use, each participant  will perform 3 exercise  and meal  bolus- related  challenges 2056 
(details below) appropriate for the age of the participant. Each challenge will be separated from [ADDRESS_1121515] assure the child has a working CGM and Control- IQ is active.  If activity is paused  during 2059 
an exercise- related challenge, the challenge may be continued to allow for continuation of the 2060 
activity if  the participant  is able and willing to continue. 2061 
Participants  will receive a guidance document for performing the challenges that includes the 2062 
following safety mitigations: 2063 
• The participant’s parent or guardian must remain with the child at all times and [ADDRESS_1121516] two hours after completion 2065 
of each  challenge. 2066 
 
 
 PEDAP
 PROTOCOL V 11.0  CLEAN  PAGE 81 OF 84 
 • The hyperglycemia safety protocol described in section 8.2.4 will be followed during 2067 
each challenge. 2068 
• The parent/guardian must have an on-call phone number for the study team prior to 2069 
initiation of each challenge. 2070 
• CGM glucose must be ≥ 120 mg/dL prior to initiation of each exercise- related 2071 
challenge.  2072 
• Exercise may not be initiated during an exercise- related challenge if the CGM trend 2073 
arrows on the study insulin pump indicate Falling glucose (down arrow) or Rapi[INVESTIGATOR_375] 2074 
Falling glucose (double down arrow). 2075 
• Snacks and glucagon must be available for use during and after each exercise- related 2076 
challenge. 2077 
• Control- IQ exercise activity mode must be activated at least [ADDRESS_1121517] 30 2079 
minutes after completion of the exercise period. 2080 
• Additional carbohydrate may be given as needed at the start  of, during, or after each 2081 
exercise- related challenge. 2082 
• The temp orary  basal rate feature of the study pump may be used if des ired to reduce 2083 
insulin delivery during the exercise period of each exercise- related challenge.  2084 
• Fingersticks will be performed for any low CGM value <70 mg/dL, and any exercise 2085 
should be stopped if BG is confirmed <70 mg/dL. Exercise may be stopped for 2086 
concerns for CGM decreasing at any time, even if CGM is >70 mg/dL. 2087 
• A parent/guardian will sleep in the same home as the child overnight and closely [ADDRESS_1121518] with the study investigat or may  be initiated at any time.  2090 
Challenge Details:  2091 
Missed Meal Bolus  Challenge : Participants  will skip their meal bolus for an afternoon meal of [ADDRESS_1121519] 20 grams carbohydrate. The meal timing and carb amount and any additional snacks 2093 
given will be recorded on a study exercise log. Additional insulin boluses may be given for 2094 
hyperglycemia as needed.  The hyperglycemia safety protocol described in section 8.2.4 will be 2095 
followed. 2096 
Full Meal Bolus Plus Exercise Challenge : Participants  will receive a full meal bolus for an [ADDRESS_1121520] 20 grams carbohydrate. The pump’s Exercise Activity setting will be 2098 
turned on upon completion of the meal. Beginning 30 minutes after  completion of the meal, a 2099 
parent /guardian will try to keep the child physically active (walking, running, playing) for at [ADDRESS_1121521] 30  minutes if possible, or longer if desired. This can be mixed with mild activity. The meal 2101 
timing and carb amount, the actual stop  and start time of exercise, any associated hypoglycemia 2102 
treatments , and any additional snacks given will be recorded on a study exercise log. 2103 
 
 
 PEDAP
 PROTOCOL V 11.0  CLEAN  PAGE 82 OF 84 
 Exercise Challenge: At least 2 hours after the child finishes an afternoon meal, a 2104 
parent/guardian will try to keep the child physically active (walking, running, playing) for at [ADDRESS_1121522] 30  minutes if possible, or longer if desired. This can be mixed with mild activity. The 2106 
pump’s Exercise Activity setting will be turned on [ADDRESS_1121523] meal prior to exercise, the actual start  and stop time of 2108 
exercise, any associated hypoglycemia treatments , and any additional snacks given will be 2109 
recorded on a study exercise log. 2110 
A challenge may be stopped for any reason, including participant non-cooperation, or concern 2111 
for hypoglycemia, or repeated hypoglycemia. 2112 
 Outcomes and Analysis Plan 2113 
A separate statistical analysis plan will be written for the Ancillary Study.  2114 
Outcomes will include the following: 2115 
Key Safety Outcomes:  2116 
• Severe hypoglycemia 2117 
• Other adverse ev ents 2118 
All adverse events will be listed. Listings will include Participant ID, the event, whether the 2119 
event was serious, whether the event was related to the study device, the event outcome, and a 2120 
description of the event. 2121 
 2122 
Other Outcomes  2123 
• CGM -measured %  <54 mg/dL  overnight (all challenge types)  2124 
• CGM -measured %  <70 mg/dL overnight (all challenge types)  2125 
• CGM -measured %  >180 mg/dL overnight (all challenge types)  2126 
• CGM -measured %  <54 mg/dL  during the two hours immediately following the start of 2127 
exercise for each exercise- related challenge  2128 
• CGM -measured % <70 mg/dL during the two hours immediately following the start of 2129 
exercise for each exercise- related challenge  2130 
• CGM -measured %  >180 mg/dL during the four hours following the announced meal, or 2131 
until the next meal bolus is given, for the missed meal bolus challenge 2132 
• CGM -measured %  >300 mg/dL during the four hours following the announced meal, or 2133 
until the next meal bolus is given, for the missed meal bolus challenge 2134 
The percentage of time spent below 54 mg/dL from 10 PM – 5:59 AM  the night of a n exercise 2135 
challenge will be compared with percentage of time spent below 54 mg/dL the previous night 2136 
using a linear mixed effects regressio n model. A point estimate, 95% confidence interval and [ADDRESS_1121524] based on the linear regression model 2138 
and a 5% level will be used to declare statistical significance. Residual values will be examined [ADDRESS_1121525] regression using 2140 
M-estimation will be used instead.  Analysis of the percentage of time spent below 70 mg/dL 10 2141 
 
 
 PEDAP
 PROTOCOL V 11.0  CLEAN  PAGE 83 OF 84 
 PM – 5:59 AM  the night of a n exercise challenge will be performed in t he same manner.  2142 
 2143 
The percentage of time spent above 180 mg/dL from 10 PM – 5:59 AM  the night of a missed 2144 
meal bolus challenge will be compared with percentage of time spent above 180 mg/dL the 2145 
previous night using a linear mixed effects regression model. A point estimate, 95% confidence [ADDRESS_1121526] based on the linear 2147 
regression model and a 5% level will be used to declare statistical significance. Residual values [ADDRESS_1121527] regression using M- estimation will be used instead.  Analysis of the percentage of time 2150 
spent above 300 mg/dL 10 PM – 5:59 AM  the night of a mis sed meal bolus challenge will be 2151 
performed in the same manner.  2152 
 2153 CGM -measured % <54 mg/dL during the two hours immediately following the start of exercise [ADDRESS_1121528]. CGM -measured % <70 mg/dL during this same period  will be analyzed in the same [ADDRESS_1121529] deviation, and range will be given for the outcomes 2159 
listed above relevant to the challenge type. Summary statistics for the overnight periods 2160 
preceding the challenges will be presented with summary statistics for each challenge type.
 2161 
Safety Monitoring 2162 
Safety ov ersight will be the same as for the main study, as described in Chapter 10:.    2163 
 
 
 PEDAP
 PROTOCOL V 11.0  CLEAN  PAGE 84 OF 84 
 Chapter 16:  References 2164 
1. Brown  S, Kovatchev B , Raghinaru D, Lum JW , Buckingham  BA, Kudva YC, Laffel  LM, 2165 
Levy CJ,  Pi[INVESTIGATOR_45905] , Wadwa RP , Dassau  E, Doyle FJ , Anderson SM, Church MM, Dadlani 2166 
V, Ekhlaspour L, Forlenza GP, Isga naitis E, Lam DW, Kollman C, and Beck RW , for the 2167 
iDCL Trial Research Group : Six-Month Randomized, Multicenter Trial of Closed-Loop [ADDRESS_1121530] 31;381(18):1707-1717. doi: 2169 
10.1056/NEJMoa1907863. [ADDRESS_1121531] E, Carria L, Emory E, Hsu LJ, Oliveri M, Kollman CK, Dokken BB, Weinzimer 2172 
SA, DeBoer MD, Buckingham BA, Cher ñavvsky D, and Wadwa R P, for the iDCL Trial  2173 
Research Group:  A Randomized T rial of Closed -Loop Control in Children with Type 1 2174 
Diabetes . N Engl J Med. 2020 Aug 27;383(9):836-845. doi: 10.1056/NEJMoa2004736. 2175 
3. Mallinckrodt CH, Clark WS, et al: Assessing responses profiles from incomplete longitudinal 2176 
clinical trial data under regula tory considerations, J. Biopharm. Stat., 2003; 13(2): 179-190. 2177 
4. Benjamini, Y. and Hochberg, Y. (1995) Controlling the false discovery rate: a practical and [ADDRESS_1121532]. Soc. B, 57, 289–300. 2179 